0000791908--12-31 2024 Q1 false 0.02 2 0.333 0.333 0.333 0.53906 0.52344 0.53906 0.52344 0000791908 xoma:ChiefInvestmentOfficerMember xoma:StockOptionInducementAwardsMember 2023-01-03 2023-01-03 0000791908 xoma:ChiefExecutiveOfficerInterimMember xoma:StockOptionInducementAwardsMember 2023-01-03 2023-01-03 0000791908 xoma:PerformanceStockUnitsMember 2023-05-31 0000791908 us-gaap:EmployeeStockOptionMember xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2024-01-01 2024-03-31 0000791908 xoma:TalpheraMember xoma:U.s.DepartmentOfDefenseMember xoma:CommercialPaymentPurchaseAgreementMember 2024-01-12 2024-01-12 0000791908 xoma:TalpheraMember xoma:AllCustomersExcludingU.s.DepartmentOfDefenseMember xoma:CommercialPaymentPurchaseAgreementMember 2024-01-12 2024-01-12 0000791908 xoma:DareMember xoma:SildenafilCreamMember xoma:ScenarioOneMember us-gaap:SubsequentEventMember xoma:RoyaltyPurchaseAgreementMember 2024-04-29 2024-04-29 0000791908 xoma:DareMember xoma:OvapreneMember xoma:ScenarioOneMember us-gaap:SubsequentEventMember xoma:RoyaltyPurchaseAgreementMember 2024-04-29 2024-04-29 0000791908 xoma:DareMember xoma:SildenafilCreamMember us-gaap:SubsequentEventMember xoma:RoyaltyPurchaseAgreementMember 2024-04-29 2024-04-29 0000791908 xoma:DareMember xoma:OvapreneMember us-gaap:SubsequentEventMember xoma:RoyaltyPurchaseAgreementMember 2024-04-29 2024-04-29 0000791908 xoma:TalpheraMember xoma:AloraPharmaceuticalsMember xoma:U.s.DepartmentOfDefenseMember xoma:AssetPurchaseAgreementAndMarketingAgreementMember 2024-01-12 2024-01-12 0000791908 xoma:TalpheraMember xoma:AloraPharmaceuticalsMember xoma:AllCustomersExcludingU.s.DepartmentOfDefenseMember xoma:AssetPurchaseAgreementAndMarketingAgreementMember 2024-01-12 2024-01-12 0000791908 xoma:TalpheraMember xoma:AloraPharmaceuticalsMember xoma:U.s.DepartmentOfDefenseMember xoma:AssetPurchaseAgreementAndMarketingAgreementMember 2023-04-01 2023-04-30 0000791908 xoma:TalpheraMember xoma:AloraPharmaceuticalsMember xoma:AllCustomersExcludingU.s.DepartmentOfDefenseMember xoma:AssetPurchaseAgreementAndMarketingAgreementMember 2023-04-01 2023-04-30 0000791908 xoma:DareMember xoma:OvapreneAndSildenafilCreamMember xoma:ScenarioOneMember us-gaap:SubsequentEventMember xoma:RoyaltyPurchaseAgreementMember 2024-04-29 2024-04-29 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementRz358Member 2017-12-06 2017-12-06 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementNonRz358ProductsMember 2017-12-06 2017-12-06 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:Tak079AndTak169Member xoma:CollaborationAgreementMember 2006-11-01 2006-11-01 0000791908 srt:ScenarioForecastMember xoma:CashReserveAccountsInterestAndAdministrativeFeesMember 2027-07-01 2027-07-01 0000791908 xoma:TalpheraMember xoma:CommercialPaymentPurchaseAgreementMember 2024-01-01 2024-03-31 0000791908 xoma:AptevoMember xoma:CommercialPaymentPurchaseAgreementMember 2024-01-01 2024-03-31 0000791908 xoma:AptevoMember srt:MinimumMember xoma:CommercialPaymentPurchaseAgreementMember 2023-06-01 2023-06-30 0000791908 xoma:AptevoMember xoma:CommercialPaymentPurchaseAgreementMember 2023-01-01 2023-12-31 0000791908 xoma:TalpheraMember 2024-01-01 2024-03-31 0000791908 xoma:AffitechResearchAsMember 2024-01-01 2024-03-31 0000791908 xoma:AgenusIncMember xoma:MerckImmunoOncologyProductMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 0000791908 xoma:AgenusIncMember xoma:IncyteImmunoOncologyAssetsMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 0000791908 xoma:AgenusIncMember xoma:MerckImmunoOncologyProductMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 2018-09-20 0000791908 xoma:NovartisPharmaAGMember xoma:IL1TargetLicenseAgreementMember 2017-08-24 2017-08-24 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:SecondRoyaltyInterestAcquisitionAgreementMember 2016-12-21 2016-12-21 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:FirstRoyaltyInterestAcquisitionAgreementMember 2016-12-21 2016-12-21 0000791908 xoma:ExarafenibAndRelatedIntellectualPropertyMember us-gaap:SubsequentEventMember xoma:ContingentValueRightsAgreementMember 2024-04-03 2024-04-03 0000791908 srt:MaximumMember dei:AdrMember xoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-05 2021-08-05 0000791908 srt:MaximumMember us-gaap:CommonStockMember xoma:TwoThousandEighteenAtMarketAgreementMember 2018-12-18 2018-12-18 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-12-15 2023-12-15 0000791908 xoma:DareMember us-gaap:SubsequentEventMember xoma:RoyaltyPurchaseAgreementMember 2024-04-29 2024-04-29 0000791908 xoma:TalpheraMember xoma:CommercialPaymentPurchaseAgreementMember 2024-01-12 2024-01-12 0000791908 xoma:LadrxMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2024-01-11 2024-01-11 0000791908 xoma:LadrxMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2024-01-01 2024-03-31 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2024-01-01 2024-03-31 0000791908 xoma:LadrxMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2024-01-01 2024-01-31 0000791908 xoma:LadrxMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-06-21 2023-06-21 0000791908 xoma:AptevoMember xoma:CommercialPaymentPurchaseAgreementMember 2023-06-01 2023-06-30 0000791908 xoma:AffitechResearchAsMember xoma:FaricimabProductMember srt:EuropeMember xoma:CommercialPaymentPurchaseAgreementMember 2022-01-01 2022-01-31 0000791908 xoma:AffitechResearchAsMember xoma:FaricimabProductMember country:US xoma:CommercialPaymentPurchaseAgreementMember 2022-01-01 2022-01-31 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2021-10-06 2021-10-06 0000791908 xoma:ViractaTherapeuticsInc.Member xoma:RoyaltyPurchaseAgreementMember 2021-03-22 2021-03-22 0000791908 xoma:PalobiofarmaSLMember xoma:RoyaltyPurchaseAgreementMember 2019-09-26 2019-09-26 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2019-09-01 2019-09-30 0000791908 xoma:AronoraIncMember xoma:SiliconValleyBankMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 2019-04-07 0000791908 xoma:AgenusIncMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 2018-09-20 0000791908 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0000791908 xoma:AgenusIncMember xoma:IncyteImmunoOncologyAssetsMember xoma:RoyaltyPurchaseAgreementMember 2018-09-20 2018-09-20 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2022-05-01 2022-05-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2022-07-01 2022-07-31 0000791908 xoma:ViractaTherapeuticsInc.Member us-gaap:SubsequentEventMember xoma:RoyaltyPurchaseAgreementMember 2024-04-23 2024-04-23 0000791908 xoma:ViractaTherapeuticsInc.Member xoma:RoyaltyPurchaseAgreementMember 2023-10-30 2023-10-30 0000791908 xoma:AgenusIncMember xoma:MerckImmunoOncologyProductMember xoma:RoyaltyPurchaseAgreementMember 2020-11-01 2020-11-30 0000791908 xoma:AgenusIncMember xoma:MerckImmunoOncologyProductMember xoma:RoyaltyPurchaseAgreementMember 2020-11-01 2020-11-30 0000791908 dei:AdrMember xoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-05 2021-08-05 0000791908 us-gaap:CommonStockMember xoma:TwoThousandEighteenAtMarketAgreementMember 2021-03-10 2021-03-10 0000791908 us-gaap:CommonStockMember xoma:TwoThousandEighteenAtMarketAgreementMember 2018-12-18 2018-12-18 0000791908 xoma:LadrxMember xoma:AldoxorubicinMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-06-21 0000791908 xoma:LadrxMember xoma:ArimoclomolMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-06-21 0000791908 xoma:LadrxMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-06-21 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2021-10-06 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2021-07-14 0000791908 xoma:AptevoMember 2024-01-01 2024-03-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember 2017-12-06 2020-10-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:FirstRoyaltyInterestAcquisitionAgreementMember 2016-12-21 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2021-07-14 2021-07-14 0000791908 xoma:TalpheraMember xoma:AloraPharmaceuticalsMember xoma:AssetPurchaseAgreementAndMarketingAgreementMember 2023-04-30 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementRz358Member 2017-12-06 0000791908 xoma:NovartisPharmaAGMember xoma:XOMA052LicenseAgreementMember 2017-08-24 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-09-30 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:Tak079AndTak169Member xoma:CollaborationAgreementMember 2006-11-01 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2019-08-01 2019-08-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:OtherAntibodiesMember xoma:CollaborationAgreementMember 2009-02-01 2009-02-28 0000791908 xoma:AronoraIncMember srt:MinimumMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 2019-04-07 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 2019-04-07 0000791908 xoma:AronoraIncMember xoma:BayerProductsMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 2019-04-07 0000791908 xoma:LadrxMember xoma:ContingentConsiderationRegulatoryMilestonesMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2024-03-31 0000791908 xoma:AffitechResearchAsMember xoma:ContingentConsiderationSalesMilestonesThreeMember xoma:CommercialPaymentPurchaseAgreementMember 2024-03-31 0000791908 xoma:AffitechResearchAsMember xoma:ContingentConsiderationSalesMilestonesOneAndTwoMember xoma:CommercialPaymentPurchaseAgreementMember 2024-03-31 0000791908 xoma:LadrxMember xoma:ContingentConsiderationRegulatoryMilestonesMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:AffitechResearchAsMember xoma:ContingentConsiderationSalesMilestonesOneAndTwoMember xoma:CommercialPaymentPurchaseAgreementMember 2023-12-31 0000791908 xoma:AptevoMember xoma:CommercialPaymentPurchaseAgreementMember 2023-03-29 0000791908 xoma:AffitechResearchAsMember xoma:ContingentConsiderationRegulatoryMilestonesMember xoma:CommercialPaymentPurchaseAgreementMember 2021-10-06 0000791908 xoma:AronoraIncMember xoma:BayerProductsMember srt:MaximumMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 xoma:LadrxMember xoma:ContingentConsiderationRegulatoryMilestonesMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-06-21 0000791908 xoma:AptevoMember xoma:CommercialPaymentPurchaseAgreementMember 2023-03-29 2023-03-29 0000791908 xoma:AffitechResearchAsMember xoma:FaricimabProductMember xoma:CommercialPaymentPurchaseAgreementMember 2021-10-06 2021-10-06 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2023-01-01 2023-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2017-12-06 2017-12-06 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-09-30 2015-09-30 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2017-08-24 2017-08-24 0000791908 xoma:ViractaTherapeuticsInc.Member xoma:RoyaltyPurchaseAgreementMember 2021-03-22 0000791908 xoma:PalobiofarmaSLMember xoma:RoyaltyPurchaseAgreementMember 2019-09-26 0000791908 xoma:AronoraIncMember xoma:NonBayerProductsMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908 xoma:AronoraIncMember xoma:BayerProductsMember xoma:RoyaltyPurchaseAgreementMember 2019-04-07 0000791908 xoma:KinnateMember us-gaap:SubsequentEventMember 2024-04-03 2024-04-03 0000791908 xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 xoma:CommonStockWarrantIssuedDecemberTwentyTwentyThreeMember xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-12-15 0000791908 2024-01-02 0000791908 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000791908 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000791908 dei:AdrMember xoma:AtMarketIssuanceSalesAgreement2021Member 2021-08-05 2024-03-31 0000791908 us-gaap:CommonStockMember xoma:TwoThousandEighteenAtMarketAgreementMember 2018-12-18 2024-03-31 0000791908 xoma:NovartisPharmaAGMember us-gaap:CommonStockMember xoma:XOMA052LicenseAgreementMember 2017-08-24 2017-08-24 0000791908 xoma:RezoluteIncMember 2020-10-01 2020-10-31 0000791908 us-gaap:RetainedEarningsMember 2024-03-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000791908 us-gaap:RetainedEarningsMember 2023-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000791908 us-gaap:RetainedEarningsMember 2023-03-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000791908 us-gaap:RetainedEarningsMember 2022-12-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000791908 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000791908 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000791908 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0000791908 us-gaap:CommonStockMember 2023-12-31 0000791908 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000791908 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000791908 us-gaap:CommonStockMember 2023-03-31 0000791908 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000791908 us-gaap:CommonStockMember 2022-12-31 0000791908 xoma:StockPriceHurdlesOfDollar45Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar45Member xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar40Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar40Member xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar35Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar35Member xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar30Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar30Member xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 us-gaap:CommonStockMember 2024-03-31 0000791908 xoma:StockOptionInducementAwardsMember 2023-01-03 0000791908 xoma:NovartisPharmaAGMember us-gaap:CommonStockMember xoma:XOMA052LicenseAgreementMember 2017-08-24 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0000791908 2023-01-01 2023-12-31 0000791908 xoma:StockOptionInducementAwardTwoMember 2023-01-01 2023-03-31 0000791908 xoma:StockOptionInducementAwardOneMember 2023-01-01 2023-03-31 0000791908 xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2024-01-01 2024-03-31 0000791908 xoma:StockOptionInducementAwardsMember 2024-01-01 2024-03-31 0000791908 xoma:PerformanceStockUnitsMember 2023-12-31 0000791908 xoma:StockPriceHurdlesOfDollar45Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar40Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar35Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar30Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 srt:ChiefExecutiveOfficerMember xoma:PerformanceStockUnitsMember 2024-01-01 2024-01-31 0000791908 xoma:PerformanceStockUnitsMember 2023-10-01 2023-10-31 0000791908 xoma:PerformanceStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-05-01 2023-05-31 0000791908 xoma:EmployeeMember us-gaap:EmployeeStockOptionMember xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2024-01-01 2024-03-31 0000791908 srt:DirectorMember us-gaap:EmployeeStockOptionMember xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember 2024-01-01 2024-03-31 0000791908 xoma:PerformanceStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-05-01 2023-05-31 0000791908 xoma:PerformanceStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-05-01 2023-05-31 0000791908 xoma:PerformanceStockUnitsMember 2023-05-01 2023-05-31 0000791908 srt:MinimumMember xoma:StockPriceHurdlesOfDollar45Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 srt:MinimumMember xoma:StockPriceHurdlesOfDollar40Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 srt:MinimumMember xoma:StockPriceHurdlesOfDollar35Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 srt:MinimumMember xoma:StockPriceHurdlesOfDollar30Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 srt:MaximumMember xoma:StockPriceHurdlesOfDollar45Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 srt:MaximumMember xoma:StockPriceHurdlesOfDollar40Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 srt:MaximumMember xoma:StockPriceHurdlesOfDollar35Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 srt:MaximumMember xoma:StockPriceHurdlesOfDollar30Member xoma:AwardDateMay2023ToOctober2023Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar45Member xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar40Member xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar35Member xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:StockPriceHurdlesOfDollar30Member xoma:AwardDateJanuary2024Member xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2024-01-01 2024-03-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2023-01-01 2023-03-31 0000791908 xoma:RezoluteIncMember us-gaap:SubsequentEventMember xoma:LicenseAgreementMember 2024-04-01 2024-04-30 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2024-01-01 2024-03-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2024-01-01 2024-03-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2024-01-01 2024-03-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2024-01-01 2024-03-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2023-01-01 2023-03-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2023-01-01 2023-03-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2023-01-01 2023-03-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2023-01-01 2023-03-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementRz358Member 2022-01-01 2022-01-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2019-01-01 2019-12-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2017-01-01 2017-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2017-01-01 2017-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-01-01 2015-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:CollaborationAgreementMember 2006-11-01 2024-03-31 0000791908 xoma:CashReserveAccountsOperatingExpensesMember 2023-12-15 0000791908 xoma:CashReserveAccountsInterestAndAdministrativeFeesMember 2023-12-15 0000791908 xoma:CashReserveAccountsInterestAndAdministrativeFeesAndOperatingExpensesMember 2023-12-15 0000791908 xoma:KinnateMember us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember xoma:ExarafenibAndRelatedIntellectualPropertyMember 2024-02-27 2024-02-27 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember 2024-01-01 2024-03-31 0000791908 xoma:NovartisPharmaAGMember xoma:XOMA052LicenseAgreementMember 2017-08-24 2017-08-24 0000791908 us-gaap:SeriesBPreferredStockMember 2024-03-31 0000791908 us-gaap:SeriesAPreferredStockMember 2024-03-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2024-03-31 0000791908 us-gaap:SeriesBPreferredStockMember 2023-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2023-12-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2023-12-31 0000791908 us-gaap:SeriesBPreferredStockMember 2024-02-21 2024-02-21 0000791908 us-gaap:SeriesAPreferredStockMember 2024-02-21 2024-02-21 0000791908 us-gaap:SeriesBPreferredStockMember 2023-10-18 2023-10-18 0000791908 us-gaap:SeriesAPreferredStockMember 2023-10-18 2023-10-18 0000791908 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2024-04-15 2024-04-15 0000791908 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2024-04-15 2024-04-15 0000791908 us-gaap:SeriesBPreferredStockMember 2024-01-15 2024-01-15 0000791908 us-gaap:SeriesAPreferredStockMember 2024-01-15 2024-01-15 0000791908 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-03-31 0000791908 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0000791908 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0000791908 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-12-31 0000791908 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000791908 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000791908 xoma:BiotechnologyValueFundLPMember xoma:XomaCorporationMember us-gaap:CommonStockMember 2024-03-31 0000791908 xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember 2023-11-30 0000791908 xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember 2022-11-10 0000791908 xoma:LeasedFacilitiesEmeryvilleCaliforniaMember 2023-01-31 0000791908 xoma:LeasedFacilitiesEmeryvilleCaliforniaMember 2023-01-01 2023-01-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-01-01 2023-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2016-12-21 2016-12-21 0000791908 xoma:RezoluteIncMember 2024-01-01 2024-03-31 0000791908 xoma:RezoluteIncMember 2023-01-01 2023-03-31 0000791908 xoma:RezoluteIncMember us-gaap:MeasurementInputSharePriceMember 2024-03-31 0000791908 xoma:RezoluteIncMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0000791908 xoma:RezoluteIncMember 2024-03-31 0000791908 xoma:RezoluteIncMember 2023-12-31 0000791908 us-gaap:EmployeeStockOptionMember 2024-03-31 0000791908 xoma:PerformanceStockUnitsMember 2024-03-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:RoyaltyInterestAcquisitionAgreementsMember 2023-12-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementDelayedDrawTermLoanMember 2023-12-15 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2024-03-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-12-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2023-12-15 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2024-03-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2023-12-31 0000791908 xoma:ViractaTherapeuticsInc.Member xoma:RoyaltyPurchaseAgreementMember 2024-03-31 0000791908 xoma:TalpheraMember xoma:CommercialPaymentPurchaseAgreementMember 2024-03-31 0000791908 xoma:PalobiofarmaSLMember xoma:RoyaltyPurchaseAgreementMember 2024-03-31 0000791908 xoma:LadrxMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2024-03-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2024-03-31 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2024-03-31 0000791908 xoma:AptevoMember xoma:CommercialPaymentPurchaseAgreementMember 2024-03-31 0000791908 xoma:AgenusIncMember xoma:RoyaltyPurchaseAgreementMember 2024-03-31 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2024-03-31 0000791908 xoma:ViractaTherapeuticsInc.Member xoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:PalobiofarmaSLMember xoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:LadrxMember xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember xoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:AronoraIncMember xoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:AptevoMember xoma:CommercialPaymentPurchaseAgreementMember 2023-12-31 0000791908 xoma:AgenusIncMember xoma:RoyaltyPurchaseAgreementMember 2023-12-31 0000791908 xoma:AffitechResearchAsMember xoma:CommercialPaymentPurchaseAgreementMember 2023-12-31 0000791908 xoma:Partner2Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0000791908 xoma:Partner1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0000791908 xoma:Partner1Member us-gaap:TradeAccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-12-31 2023-12-31 0000791908 xoma:Partner1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0000791908 xoma:TenYearWarrantsIssuedThirdRangeMember 2024-03-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember 2024-03-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember 2024-03-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember 2024-03-31 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member 2024-03-31 0000791908 xoma:TenYearWarrantsIssuedThirdRangeMember 2023-12-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember 2023-12-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember 2023-12-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember 2023-12-31 0000791908 xoma:CommonStockWarrantExercisePrice14.71Member 2023-12-31 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf50.00PerShareMember xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf42.50PerShareMember xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 xoma:CommonStockWarrantsAtExercisePriceOf35.00PerShareMember xoma:BlueOwlCommercialPaymentBackedLoanAgreementMember 2023-12-15 0000791908 2023-03-31 0000791908 2022-12-31 0000791908 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000791908 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000791908 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000791908 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000791908 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2024-12-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:CollaborationAgreementMember 2024-03-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2024-03-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2024-03-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2024-03-31 0000791908 xoma:TakedaPharmaceuticalCompanyLimitedMember xoma:CollaborationAgreementMember 2023-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2023-12-31 0000791908 xoma:NovartisPharmaAGMember xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember 2023-12-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2023-12-31 0000791908 xoma:JanssenBiotechInc.Member xoma:LicenseAgreementMember 2023-03-31 0000791908 us-gaap:WarrantMember 2024-01-01 2024-03-31 0000791908 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-03-31 0000791908 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000791908 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0000791908 xoma:BlueOwlCommercialPaymentBackedLoanAgreementInitialTermLoanMember 2024-01-01 2024-03-31 0000791908 xoma:PerformanceStockUnitsMember 2024-01-01 2024-03-31 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0000791908 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000791908 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000791908 2023-01-01 2023-03-31 0000791908 2024-03-31 0000791908 2023-12-31 0000791908 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0000791908 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000791908 dei:AdrMember 2024-01-01 2024-03-31 0000791908 2024-05-06 0000791908 2024-01-01 2024-03-31 xoma:period xoma:customer xoma:facility xoma:D xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure xoma:Right xoma:item xoma:agreement xoma:product iso4217:EUR

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

​ | ​
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the quarterly period ended March 31, 2024

OR

​ | ​
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

For the transition period from __________to__________

Commission File Number: 001-39801

XOMA Corporation

(Exact name of Registrant as specified in its charter)

Delaware |  | 52-2154066
(State or other jurisdiction of |  | (I.R.S. Employer
incorporation or organization) | ​ | Identification No.)
2200 Powell Street, Suite 310 |  |
Emeryville, California | ​ | 94608
(Address of principal executive offices) |  | (Zip Code)

​

Registrant’s telephone number, including area code: (510) 204-7200

Securities registered pursuant to Section 12(b) of the Act:

​ | ​ | ​
Title of each class: | Trading symbol(s): | Name of each exchange on which registered:
Common Stock, $0.0075 par value | XOMA | The Nasdaq Global Market
8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 | XOMAP | The Nasdaq Global Market
Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05) | XOMAO | The Nasdaq Global Market

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​ | ​ | ​ | ​ | ​
Large accelerated filer | ☐ | ​ | Accelerated filer | ☐
Non-accelerated filer | ☒ | ​ | Smaller reporting company | ☒
​ | ​ | ​ | Emerging growth company | ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 6, 2024, the registrant had 11,638,553 shares of common stock, $0.0075 par value per share, outstanding.

​

​

​

Table of Contents

​

XOMA CORPORATION

FORM 10-Q

TABLE OF CONTENTS

​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Page
Glossary of Terms and Abbreviations | ​ | 3
​ | ​ | ​ | ​ | ​
PART I | ​ | FINANCIAL INFORMATION | ​ | ​
​ | ​ | ​ | ​ | ​
Item 1. | ​ | Condensed Consolidated Financial Statements | ​ | 7
​ | ​ | ​ | ​ | ​
​ | ​ | Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 | ​ | 7
​ | ​ | ​ | ​ | ​
​ | ​ | Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023 (unaudited) | ​ | 8
​ | ​ | ​ | ​ | ​
​ | ​ | Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2024 and 2023 (unaudited) | ​ | 9
​ | ​ | ​ | ​ | ​
​ | ​ | Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 (unaudited) | ​ | 10
​ | ​ | ​ | ​ | ​
​ | ​ | Notes to Condensed Consolidated Financial Statements (unaudited) | ​ | 11
​ | ​ | ​ | ​ | ​
Item 2. | ​ | Management’s Discussion and Analysis of Financial Condition and Results of Operations | ​ | 43
​ | ​ | ​ | ​ | ​
Item 3. | ​ | Quantitative and Qualitative Disclosures About Market Risk | ​ | 51
​ | ​ | ​ | ​ | ​
Item 4. | ​ | Controls and Procedures | ​ | 52
​ | ​ | ​ | ​ | ​
PART II | ​ | OTHER INFORMATION | ​ | 52
​ | ​ | ​ | ​ | ​
Item 1. | ​ | Legal Proceedings | ​ | 52
​ | ​ | ​ | ​ | ​
Item 1A. | ​ | Risk Factors | ​ | 52
​ | ​ | ​ | ​ | ​
Item 2. | ​ | Unregistered Sales of Equity Securities and Use of Proceeds | ​ | 53
​ | ​ | ​ | ​ | ​
Item 3. | ​ | Defaults Upon Senior Securities | ​ | 54
​ | ​ | ​ | ​ | ​
Item 4. | ​ | Mine Safety Disclosures | ​ | 54
​ | ​ | ​ | ​ | ​
Item 5. | ​ | Other Information | ​ | 54
​ | ​ | ​ | ​ | ​
Item 6. | ​ | Exhibits | ​ | 55
​ | ​ | ​ | ​ | ​
Signatures | ​ | 57

​

​

​

2

Table of Contents

GLOSSARY OF TERMS AND ABBREVIATIONS

​ | ​ | ​
Abbreviations |  | Definition
2010 Plan | ​ | the Company's 2010 Long Term Incentive and Stock Award Plan, as amended
2018 Common Stock ATM Agreement | ​ | At The Market Issuance Sales Agreement with HCW dated December 18, 2018
2021 Series B Preferred Stock ATM Agreement | ​ | At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021
AAA | ​ | Assignment and Assumption Agreement
ACA | ​ | The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010
Affimed | ​ | Affimed N.V.
Affitech | ​ | Affitech Research AS
Affitech CPPA | ​ | the Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021
Agenus | ​ | Agenus, Inc. and certain affiliates
Agenus RPA | ​ | the Company's Royalty Purchase Agreement with Agenus dated September 20, 2018
Alora | ​ | Alora Pharmaceuticals, LLC
Anti-TGFβ Antibody License Agreement | ​ | the Company's License Agreement with Novartis dated September 30, 2015
April 2022 Letter Agreement | ​ | the Letter Agreement to Officer Employment Agreement dated August 7, 2017, between XOMA Corporation and Thomas Burns dated April 1, 2022
Aptevo | ​ | Aptevo Therapeutics Inc.
Aptevo CPPA | ​ | the Company’s Payment Interest Purchase Agreement with Aptevo dated March 29, 2023, referred to herein as “Aptevo Commercial Payment Purchase Agreement” or “Aptevo CPPA”
Aronora | ​ | Aronora, Inc.
Aronora RPA | ​ | the Company's Royalty Purchase Agreement with Aronora dated April 7, 2019
AstraZeneca | ​ | AstraZeneca plc
ASC | ​ | Accounting Standards Codification
ASC 310 | ​ | ASC Topic 310, Receivables
ASC 326 | ​ | ASC Topic 326, Financial Instruments – Credit Losses
ASC 450 | ​ | ASC Topic 450, Contingencies
ASC 606 | ​ | ASC Topic 606, Revenue from Contracts with Customers
ASC 805 | ​ | ASC Topic 805, Business Combinations
ASC 815 | ​ | ASC Topic 815, Derivatives and Hedging
ASC 842 | ​ | ASC Topic 842, Leases
ASU | ​ | Accounting Standards Update
Bayer | ​ | Bayer Pharma AG
Bioasis | ​ | Bioasis Technologies, Inc. and certain affiliates
Bioasis RPA | ​ | the Company's Royalty Purchase Agreement with Bioasis dated February 25, 2019
Black-Scholes Model | ​ | Black-Scholes Option Pricing Model
Blue Owl | ​ | Blue Owl Capital Corporation
Blue Owl Loan | ​ | Loan pursuant to the Blue Owl Loan Agreement
Blue Owl Loan Agreement | ​ | Loan agreement dated as of December 15, 2023, between XRL, the lenders from time to time party thereto and Blue Owl, as administrative agent
Board | ​ | the Company’s Board of Directors
B. Riley | ​ | B. Riley Securities, Inc.
BVF | ​ | Biotechnology Value Fund, L.P.

3

Table of Contents

Chiesi | ​ | Chiesi Farmaceutici S.p.A.
Company | ​ | XOMA Corporation, including its subsidiaries
CPPA | ​ | Commercial Payment Purchase Agreement
Daré | ​ | Daré Bioscience Inc.
Daré RPAs | ​ | the Company's Traditional RPA and Synthetic RPA with Daré dated April 29, 2024
Day One | ​ | Day One Biopharmaceuticals
DSUVIA® | ​ | sufentanil sublingual tablet (DZUVEO in European market)
DoD | ​ | U.S. Department of Defense
EMA | ​ | European Medicines Agency
ESPP | ​ | 2015 Employee Stock Purchase Plan, as amended
EU | ​ | European Union
Exchange Act | ​ | U.S. Securities Exchange Act of 1934
FDA | ​ | U.S. Food and Drug Administration
FDIC | ​ | Federal Deposit Insurance Corporation
GAAP | ​ | Generally accepted accounting principles
G&A | ​ | General and administrative
Gevokizumab License Agreement | ​ | the Company's License Agreement with Novartis dated August 24, 2017
HCRP | ​ | Healthcare Royalty Partners II, L.P.
HCW | ​ | H.C. Wainwright & Co., LLC
ICE® | ​ | Innate cell engager
ImmunityBio | ​ | ImmunityBio, Inc. (formerly NantCell, Inc.)
ImmunityBio License Agreement | ​ | Out-license agreement to ImmunityBio from LadRx dated July 27, 2017, related to the development and commercialization of Aldoxorubicin, as amended on September 27, 2018
IP | ​ | Intellectual Property
Janssen | ​ | Janssen Biotech, Inc.
Kinnate | ​ | Kinnate Biopharma Inc.
Kuros | ​ | Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC, collectively
Kuros RPA | ​ | the Company's Royalty Purchase Agreement with Kuros dated July 14, 2021
LadRx | ​ | LadRx Corporation (formerly CytRx Corporation)
LadRx Agreements | ​ | LadRx AAA and LadRx RPA
LadRx AAA | ​ | the Company’s Assignment and Assumption Agreement with LadRx dated June 21, 2023
LadRx RPA | ​ | the Company’s Royalty Purchase Agreement with LadRx dated June 21, 2023
Medexus | ​ | Medexus Pharmaceuticals, Inc.
Merck | ​ | Merck Sharp & Dohme Corp
Merck KGaA | ​ | Ares Trading SA
Merck KGaA License Agreement | ​ | In-license agreement from Merck KGaA to ObsEva related to ebopiprant dated June 10, 2015 and subsequently amended on July 8, 2016 (assumed by the Company as part of the ObsEva IP Acquisition Agreement)
NDA | ​ | New Drug Application
NOL | ​ | net operating loss
Novartis | ​ | Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc. and/or Novartis Vaccines and Diagnostics, Inc.
November 2022 Letter Agreement | ​ | November 1, 2022 amendment to the April 2022 Letter Agreement

4

Table of Contents

ObsEva | ​ | ObsEva SA
ObsEva IP Acquisition Agreement | ​ | Company's IP Acquisition Agreement with ObsEva dated November 21, 2022
Ology Bioservices | ​ | Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)
Organon | ​ | Organon International GmbH
Organon License Agreement | ​ | Out-license agreement to Organon from ObsEva dated July 26, 2021, related to the development and commercialization of ebopiprant (assumed by the Company as part of the ObsEva IP Acquisition Agreement)
Palo | ​ | Palobiofarma, S.L.
Palo RPA | ​ | the Company's Royalty Purchase Agreement with Palo dated September 26, 2019
Pfizer | ​ | Pfizer, Inc.
PSU | ​ | Performance stock unit
R&D | ​ | Research and development
Regeneron | ​ | Regeneron Pharmaceuticals, Inc.
Amended Retention Plan | ​ | October 25, 2022 amendment to the Retention Plan
Retention Plan | ​ | Retention and Severance Plan dated March 31, 2022
Rezolute | ​ | Rezolute, Inc., formerly Antria Bio, Inc.
Rezolute License Agreement | ​ | the Company's License Agreement with Rezolute dated December 6, 2017, as amended in March 2018, January 2019 and March 2020
RPA | ​ | Royalty Purchase Agreement
Roche | ​ | F. Hoffmann-La Roche AG
SEC | ​ | U.S. Securities and Exchange Commission
Second Bioasis RPA | ​ | the Company's Royalty Purchase Agreement with Bioasis dated November 2, 2020
Series A Preferred Stock | ​ | the 8.625% Series A cumulative, perpetual preferred stock issued in December 2020
Series B Preferred Stock | ​ | the 8.375% Series B cumulative, perpetual preferred stock issued in April 2021
Series A and Series B Preferred Stock | ​ | Series A Preferred Stock and Series B Preferred Stock, collectively ​
Series B Depositary Shares | ​ | the depositary shares, each representing 1/1000th interest in a share of Series B Preferred Stock
Sonnet | ​ | Sonnet BioTherapeutics, Inc., formerly Oncobiologics, Inc.
Sonnet Collaboration Agreement | ​ | the Company's Collaboration Agreement with Sonnet dated July 23, 2012, as amended in May 2019
SVB | ​ | Silicon Valley Bank
Takeda | ​ | Takeda Pharmaceutical Company Limited
Takeda Collaboration Agreement | ​ | the Company's Collaboration Agreement with Takeda dated November 1, 2006, as amended in February 2007 and February 2009
Talphera | ​ | Talphera, Inc. (formerly AcelRx Pharmaceuticals, Inc. or “AcelRx”)
Talphera APA | ​ | Asset Purchase Agreement dated March 12, 2023 between AcelRx (now Talphera) and Vertical related to the sale of DSUVIA from Talphera to Vertical
Talphera CPPA | ​ | the Company’s Payment Interest Purchase Agreement with Talphera dated January 11, 2024, referred to herein as “Talphera Commercial Payment Purchase Agreement” or “Talphera CPPA”
Talphera Marketing Agreement | ​ | Marketing Agreement dated April 3, 2023 between AcelRx (now Talphera) and Vertical
TGFβ | ​ | transforming growth factor beta
U.S. | ​ | United States
VABYSMO® | ​ | faricimab-svoa

5

Table of Contents

Vertical | ​ | Vertical Pharmaceuticals, LLC, a wholly-owned subsidiary of Alora
Viracta | ​ | Viracta Therapeutics, Inc.
Viracta RPA | ​ | the Company's Royalty Purchase Agreement with Viracta dated March 22, 2021, as amended March 4, 2024
XOMA | ​ | XOMA Corporation, a Delaware corporation, including subsidiaries
XRA | ​ | XRA 1 Corp.
XRL | ​ | XRL 1 LLC, a wholly-owned subsidiary of XOMA
Zevra | ​ | Zevra Therapeutics, Inc. (formerly KemPharm Denmark A/S)
Zevra APA | ​ | Asset Purchase Agreement dated May 13, 2011 between LadRx and Orphazyme ApS, and assigned to Zevra as of June 1, 2022, related to the sale of arimoclomol from LadRx to Zevra (assumed by the Company as part of LadRx AAA)

​

​

​

6

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

XOMA CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2024 |  | 2023(1)
ASSETS | ​ | (unaudited) | ​ | ​
Current assets: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 136,225 | ​ | $ | 153,290
Short-term restricted cash | ​ | ​ | 160 | ​ | ​ | 160
Short-term equity securities | ​ | ​ | 413 | ​ | ​ | 161
Trade and other receivables, net | ​ |  | 3 | ​ |  | 1,004
Short-term royalty and commercial payment receivables | ​ | ​ | 9,819 | ​ | ​ | 14,215
Prepaid expenses and other current assets | ​ |  | 270 | ​ |  | 483
Total current assets | ​ |  | 146,890 | ​ |  | 169,313
​ | ​ | ​ | ​ | ​ | ​ | ​
Long-term restricted cash | ​ | ​ | 6,016 | ​ |  | 6,100
Property and equipment, net | ​ |  | 40 | ​ |  | 25
Operating lease right-of-use assets | ​ | ​ | 364 | ​ | ​ | 378
Long-term royalty and commercial payment receivables | ​ |  | 65,577 | ​ |  | 57,952
Other assets - long term | ​ |  | 533 | ​ |  | 533
Total assets | ​ | $ | 219,420 | ​ | $ | 234,301
​ | ​ | ​ | ​ | ​ | ​ | ​
LIABILITIES AND STOCKHOLDERS’ EQUITY | ​ | ​ | ​ | ​ | ​ | ​
Current liabilities: | ​ | ​ | ​ | ​ | ​ | ​
Accounts payable | ​ | $ | 1,515 | ​ | $ | 653
Accrued and other liabilities | ​ |  | 1,299 | ​ |  | 2,768
Contingent consideration under RPAs, AAAs and CPPAs | ​ | ​ | 3,000 | ​ | ​ | 7,000
Operating lease liabilities | ​ | ​ | 55 | ​ | ​ | 54
Unearned revenue recognized under units-of-revenue method | ​ |  | 2,159 | ​ |  | 2,113
Preferred stock dividend accrual | ​ | ​ | 1,368 | ​ | ​ | 1,368
Current portion of long-term debt | ​ | ​ | 6,144 | ​ | ​ | 5,543
Total current liabilities | ​ |  | 15,540 | ​ |  | 19,499
Unearned revenue recognized under units-of-revenue method – long-term | ​ |  | 6,692 | ​ |  | 7,228
Long-term operating lease liabilities | ​ | ​ | 319 | ​ | ​ | 335
Long-term debt | ​ | ​ | 114,528 | ​ | ​ | 118,518
Total liabilities | ​ |  | 137,079 | ​ |  | 145,580
​ | ​ | ​ | ​ | ​ | ​ | ​
Commitments and Contingencies (Note 10) | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Stockholders’ equity: | ​ | ​ | ​ | ​ | ​ | ​
Preferred Stock, $0.05 par value, 1,000,000 shares authorized: | ​ | ​ | ​ | ​ | ​ | ​
8.625% Series A cumulative, perpetual preferred stock, 984,000 shares issued and outstanding at March 31, 2024 and December 31, 2023 | ​ | ​ | 49 | ​ | ​ | 49
8.375% Series B cumulative, perpetual preferred stock, 1,600 shares issued and outstanding at March 31, 2024 and December 31, 2023 | ​ | ​ | — | ​ |  | —
Convertible preferred stock, 5,003 shares issued and outstanding at March 31, 2024 and December 31, 2023 | ​ |  | — | ​ |  | —
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,636,355 and 11,495,492 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | ​ |  | 87 | ​ |  | 86
Additional paid-in capital | ​ |  | 1,314,036 | ​ |  | 1,311,809
Accumulated deficit | ​ |  | (1,231,831) | ​ |  | (1,223,223)
Total stockholders’ equity | ​ |  | 82,341 | ​ |  | 88,721
Total liabilities and stockholders’ equity | ​ | $ | 219,420 | ​ | $ | 234,301

​

The accompanying notes are an integral part of these condensed consolidated financial statements.

(1)The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

​

7

Table of Contents

​

​

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except per share amounts)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended
​ | ​ | March 31,
​ |  | 2024 |  | 2023
Revenues: | ​ | ​ | ​ | ​ | ​ | ​
Revenue from contracts with customers | ​ | $ | 1,000 | ​ | $ | —
Revenue recognized under units-of-revenue method | ​ |  | 490 | ​ |  | 437
Total revenues | ​ |  | 1,490 | ​ |  | 437
​ | ​ | ​ | ​ | ​ | ​ | ​
Operating expenses: | ​ |  | ​ | ​ |  | ​
Research and development | ​ |  | 33 | ​ |  | 54
General and administrative | ​ |  | 8,461 | ​ |  | 6,196
Arbitration settlement costs | ​ |  | — | ​ |  | 4,132
Amortization of intangible assets | ​ | ​ | — | ​ | ​ | 225
Total operating expenses | ​ |  | 8,494 | ​ |  | 10,607
​ | ​ | ​ | ​ | ​ | ​ | ​
Loss from operations | ​ |  | (7,004) | ​ |  | (10,170)
​ | ​ | ​ | ​ | ​ | ​ | ​
Other income (expense): | ​ |  | ​ | ​ |  | ​
Interest expense | ​ |  | (3,551) | ​ |  | —
Other income (expense), net | ​ |  | 1,960 | ​ |  | 357
Net loss and comprehensive loss | ​ | $ | (8,595) | ​ | $ | (9,813)
Less: accumulated dividends on Series A and Series B preferred stock | ​ | ​ | (1,368) | ​ | ​ | (1,368)
Net loss and comprehensive loss attributable to common stockholders, basic and diluted | ​ | $ | (9,963) | ​ | $ | (11,181)
Basic and diluted net loss per share attributable to common stockholders | ​ | $ | (0.86) | ​ | $ | (0.98)
Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders | ​ |  | 11,580 | ​ | ​ | 11,460

​

T he accompanying notes are an integral part of these condensed consolidated financial statements.

​

​

​

​

​

8

Table of Contents

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

(in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Series A | ​ | Series B | ​ | Convertible | ​ | ​ | ​ | Additional | ​ | ​ | ​ | Total
​ | Preferred Stock | ​ | Preferred Stock | ​ | Preferred Stock | ​ | Common Stock | ​ | Paid-In | ​ | Accumulated | ​ | Stockholders’
​ | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Capital | ​ | Deficit |  | Equity
Balance, December 31, 2023 | 984 | ​ | $ | 49 | ​ | 2 | ​ | $ | — | ​ | 5 | ​ | $ | — |  | 11,495 | ​ | $ | 86 | ​ | $ | 1,311,809 | ​ | $ | (1,223,223) | ​ | $ | 88,721
Exercise of stock options | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | 135 | ​ | ​ | 1 | ​ |  | 621 | ​ |  | — | ​ |  | 622
Issuance of common stock related to 401(k) contribution | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | 7 | ​ | ​ | — | ​ |  | 118 | ​ |  | — | ​ |  | 118
Stock-based compensation expense | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | — | ​ | ​ | — | ​ |  | 2,856 | ​ |  | — | ​ |  | 2,856
Preferred stock dividends | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | — | ​ | ​ | — | ​ |  | (1,368) | ​ |  | — | ​ |  | (1,368)
Repurchase of common stock | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | (1) | ​ | ​ | — | ​ |  | — | ​ |  | (13) | ​ |  | (13)
Net loss and comprehensive loss | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | — | ​ | ​ | — | ​ |  | — | ​ |  | (8,595) | ​ |  | (8,595)
Balance, March 31, 2024 | 984 | ​ | $ | 49 | ​ | 2 | ​ | $ | — | ​ | 5 | ​ | $ | — |  | 11,636 | ​ | $ | 87 | ​ | $ | 1,314,036 | ​ | $ | (1,231,831) | ​ | $ | 82,341

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Series A | ​ | Series B | ​ | Convertible | ​ | ​ | ​ | Additional | ​ | ​ | ​ | Total
​ | Preferred Stock | ​ | Preferred Stock | ​ | Preferred Stock | ​ | Common Stock | ​ | Paid-In | ​ | Accumulated | ​ | Stockholders’
​ | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Capital | ​ | Deficit |  | Equity
Balance, December 31, 2022 | 984 | ​ | $ | 49 | ​ | 2 | ​ | $ | — | ​ | 5 | ​ | $ | — |  | 11,454 | ​ | $ | 86 | ​ | $ | 1,306,271 | ​ | ​ | (1,182,392) | ​ | $ | 124,014
Issuance of common stock related to 401(k) contribution | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | 7 | ​ |  | — | ​ |  | 123 | ​ |  | — | ​ |  | 123
Stock-based compensation expense | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | — | ​ |  | — | ​ |  | 1,570 | ​ |  | — | ​ |  | 1,570
Preferred stock dividends | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | — | ​ |  | — | ​ |  | (1,368) | ​ |  | — | ​ |  | (1,368)
Net loss and comprehensive loss | — | ​ |  | — | ​ | — | ​ |  | — | ​ | — | ​ |  | — |  | — | ​ |  | — | ​ |  | — | ​ |  | (9,813) | ​ |  | (9,813)
Balance, March 31, 2023 | 984 | ​ | $ | 49 | ​ | 2 | ​ | $ | — | ​ | 5 | ​ | $ | — |  | 11,461 | ​ | $ | 86 | ​ | $ | 1,306,596 | ​ | $ | (1,192,205) | ​ | $ | 114,526

​

The accompanying notes are an integral part of these condensed consolidated financial statements.

​

​

9

Table of Contents

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2024 |  | 2023
Cash flows from operating activities: | ​ | ​ | ​ | ​ | ​ | ​
Net loss | ​ | $ | (8,595) | ​ | $ | (9,813)
Adjustments to reconcile net loss to net cash used in operating activities: | ​ | ​ | ​ | ​ | ​ | ​
Stock-based compensation expense | ​ |  | 2,856 | ​ |  | 1,570
Common stock contribution to 401(k) | ​ |  | 118 | ​ |  | 123
Amortization of intangible assets | ​ | ​ | — | ​ | ​ | 225
Depreciation | ​ |  | 2 | ​ |  | 1
Accretion of long-term debt discount and debt issuance costs | ​ |  | 306 | ​ |  | —
Non-cash lease expense | ​ |  | 14 | ​ |  | 47
Change in fair value of equity securities | ​ |  | (252) | ​ |  | 24
Changes in assets and liabilities: | ​ | ​ | ​ | ​ | ​ | ​
Trade and other receivables, net | ​ |  | 1,001 | ​ |  | (5)
Prepaid expenses and other assets | ​ |  | 213 | ​ |  | 269
Accounts payable and accrued liabilities | ​ |  | (105) | ​ |  | 3,122
Operating lease liabilities | ​ | ​ | (15) | ​ | ​ | (50)
Unearned revenue recognized under units-of-revenue method | ​ |  | (490) | ​ |  | (437)
Net cash used in operating activities | ​ |  | (4,947) | ​ |  | (4,924)
​ | ​ | ​ | ​ | ​ | ​ | ​
Cash flows from investing activities: | ​ | ​ | ​ | ​ | ​ | ​
Payments of consideration under RPAs, AAAs and CPPAs | ​ | ​ | (15,000) | ​ | ​ | (9,600)
Receipts under RPAs, AAAs and CPPAs | ​ | ​ | 7,771 | ​ | ​ | 2,366
Purchase of property and equipment | ​ | ​ | (17) | ​ | ​ | —
Net cash used in investing activities | ​ |  | (7,246) | ​ |  | (7,234)
​ | ​ | ​ | ​ | ​ | ​ | ​
Cash flows from financing activities: | ​ | ​ | ​ | ​ | ​ | ​
Principal payments – debt | ​ | ​ | (3,616) | ​ | ​ | —
Debt issuance costs and loan fees paid in connection with long-term debt | ​ | ​ | (581) | ​ | ​ | —
Payment of preferred stock dividends | ​ | ​ | (1,368) | ​ | ​ | (1,368)
Repurchases of common stock | ​ | ​ | (13) | ​ | ​ | —
Proceeds from exercise of options and other share-based compensation | ​ |  | 1,956 | ​ |  | —
Taxes paid related to net share settlement of equity awards | ​ |  | (1,334) | ​ |  | —
Net cash used in financing activities | ​ |  | (4,956) | ​ |  | (1,368)
​ | ​ | ​ | ​ | ​ | ​ | ​
Net decrease in cash, cash equivalents and restricted cash | ​ |  | (17,149) | ​ |  | (13,526)
Cash, cash equivalents and restricted cash at the beginning of the period | ​ |  | 159,550 | ​ |  | 57,826
Cash, cash equivalents and restricted cash at the end of the period | ​ | $ | 142,401 | ​ | $ | 44,300
​ | ​ | ​ | ​ | ​ | ​ | ​
Supplemental Cash Flow Information: | ​ | ​ | ​ |  | ​ | ​
Cash paid for interest | ​ | $ | 3,780 | ​ | $ | —
Non-cash investing and financing activities: | ​ |  |  |  | ​ | ​
Accrual of contingent consideration under the Affitech CPPA | ​ | $ | 3,000 | ​ | $ | —
Preferred stock dividend accrual | ​ | $ | 1,368 | ​ | $ | 1,368
​ | ​ | ​ | ​ | ​ | ​ | ​

​

The accompanying notes are an integral part of these condensed consolidated financial statements.

​

​

10

Table of Contents

XOMA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business

XOMA Corporation, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company’s portfolio was built through the acquisition of rights to future milestone payments, royalties and commercial payments, since its royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Company’s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. XOMA also acquires milestone and royalty revenue streams on late-stage or commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to generate royalty or milestone payments to the Company in a relatively short timeframe. The Company expects most of its future revenue to be based on milestone payments the Company may receive for milestones and royalties associated with these programs.

Liquidity and Financial Condition

The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of March 31, 2024, the Company had cash, cash equivalents and restricted cash of $142.4 million primarily related to financing cash inflows received in December 2023 pursuant to the Blue Owl Loan Agreement (see Note 8).

As of March 31, 2024, the Company had cash and cash equivalents of $136.2 million and restricted cash of $6.2 million. As of March 31, 2024, $0.2 million of restricted cash was classified as current and $6.0 million was classified as non-current. The restricted cash balance may only be used to pay interest expense, administrative fees and other allowable expenses pursuant to the Blue Owl Loan.

Based on the Company’s current cash balance and its planned spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued.

​

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with U.S. GAAP for financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial reporting. As permitted under those rules, certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 8, 2024.

These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial

11

Table of Contents

information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year, or for any other future annual or interim period.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management routinely evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, legal contingencies, contingent consideration, amortization of the Blue Owl Loan, accrued expenses and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

Actual results may differ significantly from these estimates, including estimates such as the Company’s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported. In addition, the Company’s amortization of the Blue Owl Loan is calculated based on the commercial payments expected to be received from Roche for VABYSMO under the Affitech CPPA. Any changes to the estimated commercial payments from Roche can result in a material adjustment to the interest expense and term loan balance reported.

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated statements of cash flows (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2024 |  | 2023
Cash and cash equivalents | ​ | $ | 136,225 | ​ | $ | 153,290
Restricted cash | ​ | ​ | 6,176 | ​ | ​ | 6,260
Total cash, cash equivalents and restricted cash | ​ | $ | 142,401 | ​ | $ | 159,550

​

Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. Cash equivalent balances are defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Cash equivalents held by the Company are generally in money market funds.

Cash and Cash Equivalents

As of March 31, 2024, the Company had a cash balance of $1.5 million and a cash equivalent balance of $134.7 million. As of December 31, 2023, the Company had a cash balance of $124.9 million and a cash equivalent balance of $28.4 million.

Restricted Cash

Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current.

On December 15, 2023, XRL deposited $6.3 million into reserve accounts in connection with the funding of the Blue Owl Loan (see Note 8), of which $5.8 million was deposited into a reserve account for interest and administrative fees and $0.5 million was deposited into an operating reserve account to cover operating expenses of XRL.

12

Table of Contents

Payments of interest under the Blue Owl Loan Agreement are made semi-annually using commercial payments received since the immediately preceding interest payment date under the Affitech CPPA. On each interest payment date, if the commercial payments received are less than the total interest due for the respective quarter, XRL is expected to cover the shortfall in interest payment due from the reserve account.

Payments of administrative fees under the Blue Owl Loan Agreement are made semi-annually on January 1 and July 1 of each year from the reserve account. XOMA will be required to fund an additional $0.8 million into the administrative fee escrow account on July 1, 2027.

As of March 31, 2024, the Company had a short-term restricted cash balance of $0.2 million and a long-term restricted cash balance of $6.0 million on its condensed consolidated balance sheet. As of December 31, 2023, the Company had a short-term restricted cash balance of $0.2 million and a long-term restricted cash balance of $6.1 million on its consolidated balance sheet.

Revenue Recognition

The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract on whether each promised good or service is distinct to determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.

The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.

License of Intellectual Property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).

13

Table of Contents

Milestone Payments

At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.

If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

Sale of Future Revenue Streams

The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.

Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.

Stock-Based Compensation

The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such

14

Table of Contents

as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of the expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.

The grant date fair value of PSUs with market conditions is determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.

Equity Securities

The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (see Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale.

Purchase of Rights to Future Milestones, Royalties and Commercial Payments

The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (see Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and are subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amounts are probable and estimable according to ASC 450.

The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.

Allowance for Current Expected Credit Losses

The Company evaluates the long-term royalty and commercial payment receivables on a collective (i.e., pool) basis if they share similar risk characteristics. The Company evaluates a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable

15

Table of Contents

asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record an impairment charge. The impairment charge will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset’s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made.

Asset Acquisitions

As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (see Note 4).

Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and are subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statements of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.

Cash payments related to acquired assets are reflected as an investing cash flow in the Company’s condensed consolidated statements of cash flows.

Leases

The Company leases its headquarters in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company estimated its incremental borrowing rate by adjusting the interest rate on its fully collateralized debt for the lease term length.

Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.

The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus are recognized in rent expense when incurred.

The Company has also elected not to record on the consolidated balance sheets a lease for which the term is 12 months or less and does not include a purchase option that the Company is reasonably certain to exercise.

Long-Term Debt

Long-term debt represents the Company’s term loan under the Blue Owl Loan Agreement, which the Company has accounted for as a debt financing arrangement. Interest expense is accrued using the effective interest rate method over the estimated period the loan will be repaid. The allocated debt discount and debt issuance costs have been recorded as a direct deduction from the carrying amount of the related debt in the consolidated balance sheets and are being amortized

16

Table of Contents

and recorded as interest expense throughout the expected life of the Blue Owl Loan using the effective interest rate method. The Company considered whether there were any embedded features in the Blue Owl Loan Agreement that require bifurcation and separate accounting as derivative financial instruments pursuant to ASC 815. See Note 8.

Warrants

The Company has issued warrants to purchase shares of its common stock in connection with its financing activities. The Company classifies these warrants as equity and recorded the warrants at fair value as of the date of issuance on the Company’s consolidated balance sheet with no subsequent remeasurement. The issuance date fair value of the outstanding warrants was estimated using the Black-Scholes Model. The Black-Scholes Model required inputs such as the expected term of the warrants, expected volatility and risk-free interest rate. These inputs were subjective and required significant analysis and judgment. For the estimate of the expected term, the Company used the full remaining contractual term of the warrant. The estimate of expected volatility assumption is based on the historical price volatility observed on the Company’s common stock. The risk-free rate is based on the yield available on U.S. Treasury zero-coupon issues corresponding to the expected term of the warrants.

Income Taxes

The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.

The recognition, derecognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at each reporting date. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Net Loss per Share Attributable to Common Stockholders

The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company’s convertible Series X Preferred Stock participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company’s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.

Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.

Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company’s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company’s share price and, therefore, are not included in the diluted shares until the contingency is resolved.

17

Table of Contents

Share Repurchases

The Company has a stock repurchase program that is executed through purchases made from time to time, including in the open market. The Company retires repurchased shares of common stock, reducing common stock with any excess of cost over par value recorded to accumulated deficit. Issued and outstanding shares of common stock are reduced by the number of shares repurchased. No treasury stock is recognized in the condensed consolidated financial statements. In August 2022, the Inflation Reduction Act (IRA) enacted a 1% excise tax on net share repurchases after December 31, 2022. Any excise tax incurred on share repurchases is recognized as part of the cost basis of the shares acquired.

Concentration of Risk

Cash, cash equivalents, restricted cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.

The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.

The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables.

For the three months ended March 31, 2024, two partners represented 67% and 33% of total revenues. For the three months ended March 31, 2023, one partner represented 100% of total revenues. There were no trade receivables, net as of March 31, 2024. One partner represented 100% of the trade receivables, net as of December 31, 2023.

Comprehensive (Loss) Income

Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders’ equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.

Accounting Pronouncements Recently Adopted

In November 2023, the FASB issued ASU 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company adopted annual requirements under ASU 2023-07 on January 1, 2024 and plans to adopt interim requirements under ASU 2023-07 on January 1, 2025. The Company will begin including financial statement disclosures in accordance with ASU 2023-07 in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

​

Recent Accounting Pronouncements Not Yet Adopted

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the Securities and Exchange Commission’s Disclosure Update and Simplification Initiative. ASU 2023-06 incorporates 14 of the 27 disclosure requirements published in SEC Release No. 33-10532: Disclosure Update and Simplification into various topics within the ASC. ASU 2023-06's amendments represent clarifications to, or technical corrections of, current requirements. For SEC registrants, the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. Early adoption is prohibited. The Company does not expect the standard to have a material impact on its consolidated financial statements and disclosures.

​

18

Table of Contents

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for all public entities for fiscal years beginning after December 15, 2024. Early adoption is permitted and should be applied either prospectively or retrospectively. The Company plans to adopt ASU 2023-09 and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.

​

​

3. Condensed Consolidated Financial Statements Details

Equity Securities

As of March 31, 2024 and December 31, 2023, equity securities consisted of an investment in Rezolute’s common stock of $0.4 million and $0.2 million, respectively (see Note 4). For the three months ended March 31, 2024 and 2023, the Company recognized a gain of $0.3 million and a loss of $24,000, respectively, due to the change in fair value of its investment in Rezolute’s common stock in the other income (expense), net line item of its condensed consolidated statements of operations and comprehensive loss.

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31,
​ |  | 2024 |  | 2023
Accrued incentive compensation | ​ | $ | 397 | ​ | $ | 1,203
Accrued legal and accounting fees | ​ | ​ | 674 | ​ | ​ | 791
Accrued payroll, severance and retention costs | ​ |  | 128 | ​ |  | 149
Other accrued liabilities | ​ | ​ | 100 | ​ | ​ | 625
Total | ​ | $ | 1,299 | ​ | $ | 2,768

​

Net Loss Per Share Attributable to Common Stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2024 |  | 2023
Numerator |  | ​ |  |  | ​ |
Net loss | ​ | $ | (8,595) | ​ | $ | (9,813)
Less: Series A accumulated dividends | ​ |  | (530) | ​ |  | (530)
Less: Series B accumulated dividends | ​ | ​ | (838) | ​ | ​ | (838)
Net loss attributable to common stockholders, basic and diluted | ​ | $ | (9,963) | ​ | ​ | (11,181)
​ | ​ | ​ | ​ | ​ |  | ​
Denominator | ​ |  | ​ | ​ |  | ​
Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders | ​ |  | 11,580 | ​ |  | 11,460
Basic and diluted net loss per share attributable to common stockholders | ​ | $ | (0.86) | ​ | $ | (0.98)

​

Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive.

19

Table of Contents

The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):

​

​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2024 |  | 2023
Convertible preferred stock (as converted) | ​ | 5,003 | ​ | 5,003
Common stock options |  | 1,372 | ​ | 1,548
Warrants for common stock |  | 131 | ​ | 6
Total |  | 6,506 |  | 6,557

​

For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. No shares would be issuable based on the market price of $24.05 per share as of March 31, 2024.

​

4. Licensing and Other Arrangements

Takeda

On November 1, 2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.

Under the terms of the Takeda Collaboration Agreement, the Company may receive an aggregate of up to $19.0 million relating to TAK-079 (mezagitamab) and low single-digit royalties on future sales of all products subject to this license. The Company’s right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to receive royalties expires on the later of 13.5 years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).

In February 2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company’s right to receive milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company’s right to receive royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent. In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.

The Company has received $3.0 million of milestone payments since the inception of the agreement and is eligible to receive additional milestone payments of up to $16.0 million under the Takeda Collaboration Agreement.

As of March 31, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2024 and 2023.

Rezolute

On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize RZ358 (previously known as

20

Table of Contents

“X358”) products for all indications. In addition, the Company entered into a common stock purchase agreement with Rezolute pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock in connection with any future equity financing activities.

Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to an aggregate of $232.0 million based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358.

The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute’s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the later of the date of expiration of the last valid patent claim covering the product in each country, or 12 years from the date of the first commercial sale of the product in each country. Rezolute’s future royalty obligations in the U.S. will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid patent claim, until such a claim is confirmed.

Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute’s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical study. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of 12 years from the date of the first commercial sale of the product in each country or for so long as Rezolute or its licensee is selling such product in any country, provided that any such licensee royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in each country.

The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.

No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of any future equity financing activities.

The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute’s equity financing activities and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute’s common stock (as adjusted for the 1:50 reverse stock split in October 2020).

In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement, as amended.

As of March 31, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2024 and 2023.

21

Table of Contents

Janssen

In August 2019, the Company entered into an agreement with Janssen pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain product candidates, including XOMA’s patents and know-how. Under the agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each product candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen’s achievement of certain clinical development and regulatory approval milestones. Additional milestone payments may be due for product candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen’s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The agreement will remain in effect unless terminated by mutual written agreement.

The Company concluded that the agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation.

The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen’s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of March 31, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2024 and 2023.

Novartis – Anti-TGFβ Antibody (NIS793)

On September 30, 2015, the Company and Novartis entered into the Anti-TGFβ Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (“TGFβ”) antibody program (now “NIS793”). Under the terms of the Anti-TGFβ Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGFβ Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The Anti-TGFβ Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGFβ Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety upon 180 days’ notice.

The Company concluded that there were multiple promised goods and services under the Anti-TGFβ Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015.

The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGFβ Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGFβ Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.

22

Table of Contents

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis’ obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.

In August 2023, Novartis communicated to the Company its intent to discontinue development activities related to NIS793.

As of March 31, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2024 and 2023.

Novartis – Anti-IL-1β Antibody (VPM087)

On August 24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (“VPM087”), a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087.

On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease.

Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, Novartis extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company.

Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.

23

Table of Contents

Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice.

The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.

At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of March 31, 2024 and December 31, 2023, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2024 and 2023.

Sale of Future Revenue Streams

On December 21, 2016, the Company entered into two royalty interest sale agreements (together, the “Royalty Sale Agreements”) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December 2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.

24

Table of Contents

The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company’s limited continuing involvement in the Royalty Sale Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under “units-of-revenue” method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Royalty Sale Agreements, and then applying that ratio to the period’s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.

The Company recognized $0.5 million and $0.4 million in revenue under the units-of-revenue method under these arrangements during the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, the current and non-current portions of the remaining unearned revenue recognized under the units-of-revenue method was $2.2 million and $6.7 million, respectively. As of December 31, 2023, the Company classified $2.1 million and $7.2 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.

​

5. Royalty and Commercial Payment Purchase Agreements

Short-term royalty and commercial payment receivables were $9.8 million and $14.2 million as of March 31, 2024 and December 31, 2023, respectively. Long-term royalty and commercial payment receivables were $65.6 million and $58.0 million as of March 31, 2024 and December 31, 2023, respectively.

Talphera Commercial Payment Purchase Agreement

DSUVIA was approved by the FDA in 2018 for use in adults in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora for an upfront payment, a 15% royalty on commercial net sales of DSUVIA and up to $116.5 million in sales-based milestone payments under the Talphera APA. In addition, Talphera is entitled to 75% of net sales of DSUVIA to the DoD for its services performed to support sales of DSUVIA to the DoD under the Talphera Marketing Agreement.

On January 12, 2024, the Company entered into the Talphera CPPA, pursuant to which XOMA will receive (i) 100% of the 15% royalty on commercial net sales and the sales-based milestones related to net sales of DSUVIA for sales made on and after January 1, 2024, and (ii) 100% of Talphera’s future service revenue in the amount of 75% of net sales of DSUVIA to the DoD, until the Company receives $20.0 million. Thereafter, the Company will fully retain the 15% royalty on commercial net sales of DSUVIA and will share equally with Talphera the 75% of net sales of DSUVIA to the DoD and the remaining sales-based milestone payments due from Alora.

Upon closing of the transaction, the Company paid Talphera an upfront payment of $8.0 million, which was recorded as long-term royalty receivables in its consolidated balance sheet.

During the three months ended March 31, 2024, the Company received commercial payments pursuant to the Talphera CPPA of $25,000. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty receivable balance.

Based upon limited available information, the Company is unable to reasonably estimate future net sales and the commercial payments to be received during the twelve-month period following the quarter ended March 31, 2024 and, as such, no amounts are reflected as short-term royalty and commercial payment receivables as of March 31, 2024.

25

Table of Contents

Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payment received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024.

LadRx Agreements

On June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title and interest related to arimoclomol under an asset purchase agreement dated May 13, 2011 between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory and commercial milestone payments as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under a license agreement dated July 27, 2017, as amended on September 27, 2018, between ImmunityBio and LadRx.

The purchased rights related to arimoclomol include potential regulatory and commercial milestone payments of up to $52.5 million (net of certain payment obligations of up to $9.5 million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol.

The purchased payments related to aldoxorubicin include potential regulatory and commercial milestone payments of up to $342.7 million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages for sales of other licensed products.

Upon closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $5.0 million and may pay up to an additional $6.0 million in regulatory and commercial sales milestone payments which included $5.0 million related to regulatory milestone payments and $1.0 million related to commercial sales milestone payments. The Company concluded that the regulatory milestone payments of $5.0 million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value of the regulatory milestone payments was estimated to be $1.0 million. The Company concluded the commercial milestone payment of $1.0 million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.

At the inception of the LadRx Agreements, the Company recorded $6.0 million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin payment rights acquired, which included the $5.0 million upfront payment and $1.0 million for the estimated fair value of the regulatory milestone payments.

On January 11, 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx Agreements, the Company made a $1.0 million milestone payment to LadRx in January 2024 and the LadRx contingent consideration liability was reduced to zero as of March 31, 2024.

Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024 and December 31, 2023.

Aptevo Commercial Payment Purchase Agreement

On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B.

The Company is eligible to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 until the first quarter of 2035, and will be entitled to milestone payments of up to $5.3 million.

26

Table of Contents

At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables in its consolidated balance sheet which included a $9.6 million upfront payment and a $50,000 one-time payment, which would be due if XOMA received more than $0.5 million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $50,000 was probable and reasonably estimable. Therefore, the payment was recorded as a contingent liability under ASC 450 in the consolidated balance sheet at inception. The Company paid the one-time payment of $50,000 in June 2023 when related receipts exceeded $0.5 million.

During the year ended December 31, 2023 the Company received total commercial payments pursuant to the Aptevo CPPA of $1.7 million.

During the three months ended March 31, 2024, the Company received commercial payments pursuant to the Aptevo CPPA of $0.4 million. In accordance with the cost recovery method, the cash received was recorded as a direct reduction of the long-term royalty receivable balance.

Though the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it has a more accurate projection of the commercial payments expected for the twelve-month period following the condensed consolidated balance sheet dates. As such, as of March 31, 2024 and December 31, 2023, the Company recorded $2.0 million as short-term royalty and commercial payment receivables.

Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payment received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024 and December 31, 2023.

Agenus Royalty Purchase Agreement

On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (“Incyte”) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestone payments related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid-teen digit percentages of applicable net sales.

In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company’s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.

Under the terms of the Agenus RPA, the Company paid Agenus an upfront payment of $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets.

In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone payment under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivable balance.

As of March 31, 2024, no payments were probable to be received under the Agenus RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestone and royalty payments received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024 and December 31, 2023.

27

Table of Contents

Aronora Royalty Purchase Agreement

On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone and option payments (the “Non-Royalties”) related to five anti-thrombotic hematology product candidates. Three candidates were subject to Aronora’s collaboration with Bayer (the “Bayer Products”), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the “non-Bayer Products”) for which the Company will receive a low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company’s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economic terms as the non-Bayer Products.

Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the “Aronora Contingent Consideration”). Pursuant to the Aronora RPA, if the Company receives at least $25.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the “Royalty Milestones”). The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. Royalties per product in excess of $250.0 million are retained by the Company.

At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable.

As of March 31, 2024, no payments were probable to be received under the Aronora RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024 and December 31, 2023. Based on communications in April 2024, the Company will be evaluating the status of the partnered programs for potential impairment in the second quarter of 2024.

Palobiofarma Royalty Purchase Agreement

On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six product candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin’s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the “Palo Licensed Products”) that are being developed by Palo.

Under the terms of the Palo RPA, the Company paid Palo an upfront payment of $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties’ entry into the Palo RPA on September 26, 2019. At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet.

As of March 31, 2024, no payments were probable to be received under the Palo RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024 and December 31, 2023.

28

Table of Contents

Viracta Royalty Purchase Agreement

On March 22, 2021, the Company entered into the Viracta RPA, as amended March 4, 2024, pursuant to which the Company acquired the right to receive future royalties, milestone payments and other payments related to two clinical-stage drug candidates for an upfront payment of $13.5 million. The first candidate, DAY101 (a pan-RAF kinase inhibitor), is being developed by Day One, and the second candidate, vosaroxin (a topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestone payments, potential royalties on sales, if approved, and a portion of potential other payments related to DAY101, excluding up to $5.0 million retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved.

At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet.

On October 30, 2023, the Company earned a $5.0 million milestone payment pursuant to the Viracta RPA related to the FDA’s acceptance of Day One’ NDA for tovorafenib. In accordance with the cost recovery method, the $5.0 million milestone payment received was recorded as a direct reduction of the recorded long-term royalty receivable balance.

Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024 and December 31, 2023.

Kuros Royalty Purchase Agreement

On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals’ vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestone payments.

At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet.

In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.

As of March 31, 2024, no payments were probable to be received under the Kuros RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestone payments and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024 and December 31, 2023.

Affitech Commercial Payment Purchase Agreement

On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which included the $6.0 million upfront payment and $8.0 million in regulatory milestone payments in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should

29

Table of Contents

be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of up to $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.

In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone payment tied to the U.S. marketing approvals and a $3.0 million milestone payment tied to the EC approvals.

Commercial payments are due from Roche within 60 days of December 31 and June 30 of each year. In accordance with the cost recovery method, commercial payments received are recorded as direct reductions of short-term and long-term receivable balances, as applicable.

During the three months ended March 31, 2024, the Company received $7.4 million from Roche.

Though the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received under the agreement, it has a more accurate projection of the commercial payments expected for the twelve-month period following the consolidated balance sheet dates. As such, as of March 31, 2024 and December 31, 2023, the Company recorded $7.8 million and $12.2 million, respectively, as short-term royalty and commercial payment receivables.

The achievement of the first and second sales-based milestone payments under the Affitech CPPA was considered probable as of December 31, 2023, and as such the Company recognized a $6.0 million contingent liability in contingent consideration under RPAs, AAAs and CPPAs in its consolidated balance sheet. The sales milestones were achieved in 2023 and in the first quarter of 2024, the Company paid Affitech $6.0 million and the related contingent liability balance was reduced to zero in its condensed consolidated balance sheet as of March 31, 2024.

Based on reported first quarter of 2024 sales of VABYSMO, the achievement of the third sales-based milestone payment under the Affitech CPPA was considered probable as of March 31, 2024, and the Company recognized a $3.0 million contingent liability in the condensed consolidated balance sheet. The Company may pay up to $3.0 million in an additional sales-based milestone payment upon the achievement of one remaining incremental sales milestone in the future. The final milestone was not assessed as probable and as a result is not recorded as a contingent liability as of March 31, 2024.

Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of March 31, 2024 and December 31, 2023.

30

Table of Contents

The following table summarizes the royalty and commercial payment receivable activities during the three months ended March 31, 2024 (in thousands):

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Short-Term | Long-Term
Balance as of January 1, 2024 |  | $ | 14,215 | $ | 57,952
Acquisition of royalty and commercial payment receivables: | ​ | ​ | ​ | ​ | ​
Talphera | ​ |  | — |  | 8,000
Receipt of royalty and commercial payments: | ​ | ​ | ​ | ​ | ​
Affitech | ​ | ​ | (7,396) | ​ | —
Aptevo | ​ | ​ | (350) | ​ | —
Talphera | ​ | ​ | — | ​ | (25)
Reclassification to short-term royalty and commercial payment receivables: | ​ | ​ | ​ | ​ | ​
Aptevo | ​ | ​ | 350 | ​ | (350)
Recognition of contingent consideration: | ​ | ​ | ​ | ​ | ​
Affitech | ​ | ​ | 3,000 | ​ | —
Balance as of March 31, 2024 | ​ | $ | 9,819 | $ | 65,577

​

​

6. Fair Value Measurements

The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

31

Table of Contents

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value Measurements at March 31, 2024 Using:
​ | ​ | Quoted Prices in | ​ | Significant Other | ​ | Significant | ​ | ​ | ​
​ | ​ | Active Markets for | ​ | Observable | ​ | Unobservable | ​ | ​ | ​
​ | ​ | Identical Assets | ​ | Inputs | ​ | Inputs | ​ | ​ | ​
​ |  | (Level 1) |  | (Level 2) |  | (Level 3) |  | Total
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 134,729 | ​ | $ | — | ​ | $ | — | ​ | $ | 134,729
Total cash equivalents | ​ | ​ | 134,729 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 134,729
Equity securities | ​ | ​ | 413 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 413
Total financial assets | ​ | $ | 135,142 | ​ | $ | — | ​ | $ | — | ​ | $ | 135,142
Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ | $ | —

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value Measurements at December 31, 2023 Using:
​ | ​ | Quoted Prices in | ​ | Significant Other | ​ | Significant | ​ | ​ | ​
​ | ​ | Active Markets for | ​ | Observable | ​ | Unobservable | ​ | ​ | ​
​ | ​ | Identical Assets | ​ | Inputs | ​ | Inputs | ​ | ​ | ​
​ |  | (Level 1) |  | (Level 2) |  | (Level 3) |  | Total
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash equivalents: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds | ​ | $ | 28,352 | ​ | $ | — | ​ | $ | — | ​ | $ | 28,352
Total cash equivalents | ​ | ​ | 28,352 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 28,352
Equity securities | ​ | ​ | 161 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 161
Total financial assets | ​ | $ | 28,513 | ​ | $ | — | ​ | $ | — | ​ | $ | 28,513
Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Contingent consideration under RPAs, AAAs and CPPAs, measured at fair value | ​ | $ | — | ​ | $ | — | ​ | $ | 1,000 | ​ | $ | 1,000

​

Equity Securities

The equity securities consisted of an investment in Rezolute’s common stock and are classified on the condensed consolidated balance sheets as current assets as of March 31, 2024 and December 31, 2023. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. As of March 31, 2024 and December 31, 2023 the Company valued the equity securities using the closing price for Rezolute’s common stock traded on the Nasdaq Stock Market of $2.55 and $0.99, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.

Contingent Consideration Measured at Fair Value

During the three months ended March 31, 2024, the contingent liability recorded pursuant to the LadRx Agreements decreased to zero after the Company paid LadRx $1.0 million upon achievement of a related regulatory milestone in January 2024 (Note 5).

As of March 31, 2024, the estimated fair value of the remaining LadRx contingent consideration liability is zero as it represents the future consideration that is contingent upon the achievement of a specified regulatory milestone for the product candidate related to aldoxorubicin. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of aldoxorubicin. Such contingent

32

Table of Contents

consideration is remeasured at fair value at each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss until settlement.

7. Lease Agreement

The Company leases one facility in Emeryville, California under an operating lease. In January 2023, the Company amended the original lease to extend the lease term five months from its original expiration of February 28, 2023 to July 31, 2023 (the “amended lease agreement” or the “amended lease”).

The Company retained no option to further extend, renew or terminate the amended lease under the amended terms and all other material terms and conditions, including the monthly base rent, remained consistent with the original lease.

In accordance with ASC 842, the Company accounted for the amendment to extend the lease term as a modification of the original lease and, as such, remeasured the lease liability and recognized a corresponding adjustment to the right-of-use asset of $0.1 million to reflect the changes in the lease payments due to the extended lease term.

On June 27, 2023, the Company executed the second lease amendment for its corporate headquarters lease in Emeryville, California with the same counterparty, in a different location in the same building to replace its existing amended lease which expired in July 2023 (the “new lease agreement” or the “new lease”). The new lease agreement commenced on November 10, 2023 and has a term of 65 months.

Under the new lease agreement, the Company retained access to its original premises under the amended lease which expired in July 2023, until the new premises became available on November 10, 2023. Payments made between when the lease expired in July 2023 and the commencement date of the new premises of November 10, 2023 were recorded as variable lease costs in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2023.

In accordance with ASC 842, the Company accounted for the new lease as a separate contract and the Company recognized an operating lease right-of-use assets of $0.4 million and operating lease liabilities of $0.4 million on November 10, 2023, the commencement date of the lease.

The following table summarizes maturity of the new lease through the 65-month term of the Company’s operating lease liabilities as of March 31, 2024 (in thousands):

​ | ​ | ​ | ​
Year | ​ | Rent Payments
2024 (excluding the three months ended March 31, 2024) |  | $ | 60
2025 |  | ​ | 85
2026 |  | ​ | 88
2027 | ​ | ​ | 91
2028 | ​ | ​ | 102
Thereafter |  | ​ | 36
Total undiscounted lease payments | ​ | ​ | 462
Present value adjustment | ​ | ​ | (88)
Total net lease liability | ​ | $ | 374

​

As of March 31, 2024 and December 31, 2023, the total net lease liability was $0.4 million.

As of December 31, 2023, the Company’s current and non-current operating lease liabilities were $0.1 million and $0.3 million, respectively.

33

Table of Contents

As of March 31, 2024, the Company’s current and non-current operating lease liabilities were $0.1 million and $0.3 million, respectively.

The following table summarizes the cost components of the Company’s operating leases for the three months ended March 31, 2024 and 2023 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended March 31,
​ |  | 2024 |  | 2023
Lease costs: | ​ | ​ | ​ | ​ | ​ | ​
Operating lease cost | ​ | $ | 22 |  | $ | 48
Variable lease cost (1) | ​ | ​ | (2) |  | ​ | 5
Total lease costs | ​ | $ | 20 | ​ | $ | 53

​

| (1) | Under the terms of the original, amended and new lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees. The negative balance for the period ended March 31, 2024 was due to the lessor’s reconciliation of variable lease costs from which a credit was due to the Company.

​

The following information represents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended March 31,
​ |  | 2024 | ​ | 2023
Cash paid for amounts included in the measurement of lease liabilities | ​ |  | ​ | ​ |  | ​
Operating cash flows under operating leases | ​ | $ | 23 | ​ | $ | 52

​

The following information represents supplemental disclosure for the condensed consolidated statements of cash flows related to operating leases (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | March 31, | ​ | December 31,
​ |  | 2024 | ​ | 2023
Weighted-average remaining lease term | ​ | 5.08 years | ​ | ​ | 5.33 years | ​
Weighted-average discount rate | ​ | 8.50 | % | ​ | 8.50 | %

​

​

8. Long-Term Debt

On December 15, 2023, XOMA transferred to XRL, a newly formed wholly owned subsidiary, all its rights, title and interest in the commercial payments from Roche’s VABYSMO under the Affitech CPPA and related assets (the “Commercial Payments”). The VABYSMO-related assets and rights transferred to XRL are referred to herein as the “Transferred Assets.”

Simultaneously, XRL entered into the Blue Owl Loan Agreement with Blue Owl and lenders, pursuant to which XRL was extended certain senior secured credit facilities in an aggregate principal amount of up to $140.0 million. The principal and interest of the loan are to be paid from the Commercial Payments. XRL is obligated to make semi-annual interest payments, starting in March 2024, at a fixed rate of 9.875% per annum until the commercial payment-backed loan is repaid, at which time the Commercial Payments will revert back to XOMA. On each interest payment date, any shortfall in interest payment will be paid from the interest reserve, any uncured shortfall in interest payment that exceeds the interest reserve will increase the outstanding principal amount of the loan, and any Commercial Payment in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid.

The loan matures on December 15, 2038, provided that XRL may repay it in full at any time prior to December 15, 2038, subject to the terms of the Blue Owl Loan Agreement. The Blue Owl Loan includes (i) an initial term loan in an

34

Table of Contents

aggregate principal amount equal to $130.0 million and (ii) a delayed draw term loan in an aggregate principal amount of $10.0 million to be funded at the option of the XRL upon receipt by the lenders of payments of principal and interest from the proceeds of Commercial Payments in excess of an agreed upon amount on or prior to March 15, 2026.

The payment obligations under the Blue Owl Loan Agreement are limited to XRL, and Blue Owl has no recourse under the Blue Owl Loan Agreement against XOMA or any assets other than the Transferred Assets and XOMA’s equity interest in XRL. In connection with the Blue Owl Loan Agreement, (i) XRL granted Blue Owl a first-priority perfected lien on, and security interest in, (a) the Commercial Payments and the proceeds thereof, in each case under the Affitech CPPA and (b) all other assets of XRL and (ii) XOMA granted Blue Owl a first-priority perfected lien on, and security interest in 100% of the equity of XRL. The Blue Owl Loan Agreement contains other customary terms and conditions, including representations and warranties, as well as indemnification obligations in favor of Blue Owl.

On December 15, 2023, the Company borrowed the initial term loan of $130.0 million and received $119.6 million, net of $4.1 million in fees and lender expenses and $6.3 million that was deposited into reserve accounts to pay interest, administrative fees and XRL’s operating expenses (see Note 2). The Company also incurred $0.6 million of direct issuance costs related to the Blue Owl Loan Agreement.

In connection with the Blue Owl Loan Agreement, XOMA issued to Blue Owl and certain funds affiliated with Blue Owl warrants to purchase: (i) up to 40,000 shares of XOMA’s common stock at an exercise price of $35.00 per share; (ii) up to 40,000 shares of XOMA’s common stock at an exercise price of $42.50 per share; and (iii) up to 40,000 shares of XOMA’s common stock at an exercise price of $50.00 per share (collectively, the “Blue Owl Warrants”). The fair value of the Blue Owl Warrants was determined using the Black-Scholes Model (see Note 2) and was estimated to be $1.5 million. As of March 31, 2024, all Blue Owl Warrants were outstanding.

The initial term loan of $130.0 million is carried at amortized cost. Amortization of the initial term loan is applied under the expected-effective-yield approach using the retrospective interest method. As of December 31, 2023, the effective interest rate was determined to be 11.01%. The Company recorded a debt discount of $5.3 million, which included $3.8 million in allocated fees and lender expenses and $1.5 million for the fair value of the Blue Owl Warrants. The Company also recorded $0.6 million in direct debt issuance costs allocated to the initial term loan. The Company will accrete both the debt discount of $5.3 million and $0.6 million of direct debt issuance costs over the expected term of the initial term loan.

As of the closing date of December 15, 2023, the Company recorded the $0.3 million allocated costs for the delayed draw term loan commitment as a non-current asset in other assets - long term in the consolidated balance sheet and will reclassify the amount as a debt discount when the delayed draw term loan is drawn. As of March 31, 2024, no amount had been drawn from the delayed draw term loan.

The carrying value of the short and long-term portion of the initial term loan was $5.5 million and $118.5 million, respectively, as of December 31, 2023. The Company recorded $0.6 million in interest expense during the year ended December 31, 2023.

In March 2024, XRL made a semi-annual payment of $7.4 million which included an interest payment of $3.8 million and principal repayment of $3.6 million. The carrying value of the short and long-term portion of the initial term loan was $6.1 million and $114.5 million, respectively, as of March 31, 2024. As of March 31, 2024, the effective interest rate was determined to be 11.05%. The Company recorded $3.6 million in interest expense during the three months ended March 31, 2024. As of March 31, 2024, the Company had an unaccreted debt discount of $5.1 million and unaccreted direct issuance costs of $0.6 million to be accreted over the expected remaining term of the initial term loan.

35

Table of Contents

The following table summarizes the impact of the initial term loan on the Company’s condensed consolidated balance sheet as of March 31, 2024 (in thousands):

​ | ​ | ​ | ​
​ |  | March 31, 2024
Gross principal | ​ | $ | 130,000
Principal repayments | ​ | ​ | (3,616)
Unaccreted debt discount and debt issuance costs | ​ | ​ | (5,712)
Total carrying value net of principal repayments, unaccreted debt discount and debt issuance costs | ​ | ​ | 120,672
Less: current portion of long-term debt | ​ | ​ | (6,144)
Long-term debt | ​ | $ | 114,528

​

Long-term debt on the Company’s condensed consolidated balance sheet as of March 31, 2024 and consolidated balance sheet as of December 31, 2023 includes only the carrying value of the Blue Owl Loan. The carrying value of the Blue Owl Loan as of December 31, 2023 was $124.0 million.

Aggregate projected future principal payments of the initial term loan as of March 31, 2024, are as follows (in thousands):

​ | ​ | ​ | ​
Year Ending December 31, | ​ | Payments
2024 (excluding the three months ended March 31, 2024) |  | $ | 3,588
2025 |  | ​ | 10,246
2026 |  | ​ | 15,404
2027 | ​ | ​ | 19,609
2028 | ​ | ​ | 23,585
Thereafter |  | ​ | 53,952
Total payments | ​ | $ | 126,384

​

Accretion of debt discounts and issuance costs are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2024 relates to the initial term loan (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended
​ | ​ | March 31,
​ |  | 2024 |  | 2023
Accrued interest expense | ​ | $ | 3,245 | ​ | $ | —
Accretion of debt discount and debt issuance costs | ​ |  | 306 | ​ |  | —
Total interest expense | ​ | $ | 3,551 | ​ | $ | —

​

​

9. Common Stock Warrants

As of March 31, 2024 and December 31, 2023, the following common stock warrants were outstanding:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ |  | Exercise Price |  | March 31, |  | December 31,
Issuance Date | ​ | Expiration Date | ​ | Balance Sheet Classification | ​ | per Share | ​ | 2024 | ​ | 2023
May 2018 |  | May 2028 |  | Stockholders’ equity | ​ | $ | 23.69 |  | 6,332 |  | 6,332
March 2019 | ​ | March 2029 | ​ | Stockholders’ equity | ​ | $ | 14.71 | ​ | 4,845 | ​ | 4,845
December 2023 | ​ | December 2033 | ​ | Stockholders’ equity | ​ | $ | 35.00 | ​ | 40,000 | ​ | 40,000
December 2023 | ​ | December 2033 | ​ | Stockholders’ equity | ​ | $ | 42.50 | ​ | 40,000 | ​ | 40,000
December 2023 | ​ | December 2033 | ​ | Stockholders’ equity | ​ | $ | 50.00 | ​ | 40,000 | ​ | 40,000
​ |  |  |  |  | ​ |  |  |  | 131,177 |  | 131,177

​

​

​

36

Table of Contents

10. Commitments and Contingencies

Collaborative Agreements, Royalties and Milestone Payments

The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company’s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of March 31, 2024.

Contingent Consideration

Pursuant to the Company’s agreements with Aronora, Kuros, Affitech and LadRx the Company has committed to pay the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones, and LadRx regulatory and commercial sales milestones.

As of December 31, 2023, the Company recorded $1.0 million for the LadRx contingent consideration that represented the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin at the inception of the LadRx Agreements. During the three months ended March 31, 2024, the contingent liability decreased to zero after the Company paid LadRx $1.0 million upon the FDA’s acceptance of the arimoclomol NDA resubmission (Note 5). As of March 31, 2024, the Company recorded zero for the LadRx contingent consideration as the estimated fair value of the potential future payment upon the achievement of regulatory milestones related to aldoxorubicin was negligible. Such contingent consideration related to regulatory milestones is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net.

During the year ended December 31, 2023, certain sales milestones related to VABYSMO pursuant to the Affitech CPPA were assessed to be probable under ASC 450. As such, a $6.0 million liability was recorded in contingent consideration under RPAs, AAAs and CPPAs and a corresponding $6.0 million asset was recorded under long-term royalty and commercial payment receivables on the consolidated balance sheet. During the three months ended March 31, 2024, this contingent liability decreased to zero after the Company paid Affitech $6.0 million upon the achievement of the related commercial sales milestones (Note 5).

During the three months ended March 31, 2024, a sales milestone related to VABYSMO pursuant to the Affitech CPPA was assessed to be probable under ASC 450. As such, a $3.0 million liability was recorded in contingent consideration under RPAs, AAAs, and CPPAs and a corresponding $3.0 million asset was recorded under short-term royalty and commercial payment receivables on the condensed consolidated balance sheet.

The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, remaining Affitech Sales Milestones and LadRx commercial sales milestone will be recorded when the amounts, by product, are estimable and probable.

As of March 31, 2024, none of the Aronora Royalty Milestones, Kuros Sales Milestones, remaining Affitech Sales Milestone and LadRx commercial sales milestone were assessed to be probable and as such, no liability was recorded on the condensed consolidated balance sheet.

11. Stock Based Compensation

The Company may grant qualified and non-qualified stock options, common stock, PSUs and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company’s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day

37

Table of Contents

of the purchase period. The ESPP includes a rollover mechanism for the purchase price if the fair market value of the Company’s common stock on the purchase date is less than the fair market value of the Company’s common stock on the first trading day of the offering period.

Stock Options and Other Benefit Plans

Stock Option Plans

2010 Plan Stock Options

Stock options issued under the 2010 Plan generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. No stock options were granted under the 2010 Plan during the three months ended March 31, 2024 and 2023.

Stock Option Inducement Awards

On December 30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer and Bradley Sitko as the Company’s Chief Investment Officer, effective as of January 1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted two separate awards of non-qualified stock options on January 3, 2023 (collectively, the “Stock Option Inducement Awards”) when the Company’s stock price was $18.66 per share.

The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan. More information on the Stock Option Inducement Awards granted during the three months ended March 31, 2023 can be found in Note 10 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 8, 2024.

The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the first quarter of 2023 was $11.91. The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during the first quarter of 2023 was $14.68. No Stock Option Inducement Awards were granted during the three months ended March 31, 2024.

The activity for all stock options for the three months ended March 31, 2024 was as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted |  | Weighted | ​ | ​
​ | ​ | ​ | ​ | Average | ​ | Average | ​ | Aggregate
​ | ​ | ​ | ​ | Exercise | ​ | Contractual | ​ | Intrinsic
​ | ​ | Number of | ​ | Price | ​ | Remaining Term | ​ | Value
​ | ​ | shares | ​ | Per Share | ​ | (in years) | ​ | (in thousands)
Outstanding at January 1, 2024 | ​ | ​ | 2,730,068 | ​ | $ | 20.88 |  | ​ | 6.29 | ​ | $ | 10,638
Granted |  | ​ | — | ​ |  | — |  | ​ | ​ |  | ​ |
Exercised |  | ​ | (134,959) | ​ |  | 4.61 |  | ​ | ​ |  | ​ |
Forfeited, expired or cancelled | ​ | ​ | (26,014) | ​ |  | 178.20 |  | ​ | ​ |  | ​ |
Outstanding at March 31, 2024 | ​ | ​ | 2,569,095 | ​ | $ | 20.15 |  | ​ | 6.27 | ​ | $ | 17,723
Exercisable at March 31, 2024 | ​ | ​ | 2,009,056 | ​ | $ | 19.12 |  | ​ | 5.60 | ​ | $ | 16,131

​

The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2024 was $2.5 million. No stock options were exercised during the three months ended March 31, 2023.

38

Table of Contents

The Company recorded $1.1 million in stock-based compensation expense related to stock options during the three months ended March 31, 2024. As of March 31, 2024, $7.0 million of total unrecognized compensation expense related to stock options was expected to be recognized over a weighted average period of 2.4 years.

Performance Stock Unit Awards

In May 2023, the Company granted employees 430,400 PSUs under the 2010 Plan.

The PSUs are subject to market-based vesting conditions and the number of PSUs vested will be based on the stock price of the Company’s common stock as compared to four stock price hurdles over a three-year period from the May 2023 grant date (the “performance period”). A stock price hurdle is considered attained when, at any time during the performance period, the Company’s volume-weighted average stock price equals or exceeds the hurdle stock price value for 30 consecutive calendar days. Upon attainment of a stock price hurdle, one third of the earned PSUs will vest immediately upon achievement, one third will vest upon the two-year anniversary of the grant date and one third will vest on the three-year anniversary of the grant date. If no stock price hurdle is attained during the performance period, then no PSUs will vest. In October 2023, the Company granted an additional 18,200 PSUs under the 2010 Plan with generally the same terms as the May 2023 PSU grants.

In connection with Mr. Hughes’ appointment to full-time Chief Executive Officer in January 2024, the Company granted Mr. Hughes 275,000 PSUs under the 2010 Plan with generally the same terms as the May 2023 PSU grants.

Fair Value Assumptions of Performance Stock Unit Awards

​

The fair value of the PSUs granted was estimated based on Monte Carlo valuation model which incorporates into the valuation the possibility that the stock price hurdles may not be satisfied.

The range of grant date fair values of the PSUs granted in 2023 was estimated as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | Derived
Hurdle Price | ​ | Number of | ​ | Fair Value | ​ | Service Period
Per PSU | ​ | PSUs | ​ | Per Share | ​ | (in years)
$ | 30.00 | ​ | ​ | 243,550 |  | $ | 11.42-17.45 | ​ | ​ | 0.69-2.59
$ | 35.00 | ​ | ​ | 91,239 |  | $ | 10.16-16.07 |  | ​ | 0.93-2.59
$ | 40.00 | ​ | ​ | 60,024 |  | $ | 9.07-14.84 |  | ​ | 1.12-2.59
$ | 45.00 | ​ | ​ | 53,787 |  | $ | 8.12-13.72 |  | ​ | 1.27-2.59
​ | ​ | ​ | ​ | 448,600 |  | ​ | ​ | ​ | ​ | ​

​

The grant date fair values of the PSUs granted in January 2024 was estimated as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | Derived
Hurdle Price | ​ | Number of | ​ | Fair Value | ​ | Service Period
Per Share | ​ | PSUs | ​ | Per Share | ​ | (in years)
$ | 30.00 | ​ | ​ | 160,078 |  | $ | 18.42 | ​ | ​ | 0.74
$ | 35.00 | ​ | ​ | 53,350 |  | $ | 17.24 | ​ | ​ | 0.96
$ | 40.00 | ​ | ​ | 32,835 |  | $ | 16.14 | ​ | ​ | 1.15
$ | 45.00 | ​ | ​ | 28,737 | ​ | $ | 15.13 | ​ | ​ | 1.31
​ | ​ | ​ | ​ | 275,000 |  | ​ | ​ | ​ | ​ | ​

​

The Company estimates that it will recognize total stock-based compensation expense of approximately $11.7 million in aggregate for the PSUs granted in May 2023, October 2023 and January 2024 using the graded expense attribution method over the requisite service period of each tranche. If the stock price hurdles are met sooner than the requisite service period, the stock-based compensation expense for the respective stock price hurdle will be accelerated.

39

Table of Contents

Stock-based compensation expense will be recognized over the requisite service period if the grantees continue to provide service to the Company, regardless of whether the PSU stock price hurdles are achieved.

​

The activity for all PSUs for the three months ended March 31, 2024 was as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted
​ | ​ | ​ | ​ | Average
​ | ​ | ​ | ​ | Grant Date
​ | ​ | Number of | ​ | Fair Value
​ | ​ | Unvested PSUs | ​ | Per Share
Unvested balance at January 1, 2024 | ​ | ​ | 448,600 | ​ | $ | 15.40
Granted |  | ​ | 275,000 | ​ |  | 17.58
Vested |  | ​ | — | ​ |  | —
Forfeited | ​ | ​ | — | ​ |  | —
Unvested balance at March 31, 2024 | ​ | ​ | 723,600 | ​ | $ | 16.23

​

The Company recorded $1.8 million in stock-based compensation expense related to the PSUs during the three months ended March 31, 2024. As of March 31, 2024, there was $7.1 million unrecognized stock-based compensation expense related to outstanding PSUs granted to employees, with a weighted-average remaining recognition period of 1.13 years.

​

Stock-based Compensation Expense

All stock-based compensation expense is recorded in G&A expense. The following table shows total stock-based compensation expense for stock options, PSUs and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31,
​ |  | 2024 |  | 2023
Total stock-based compensation expense included in G&A | ​ | $ | 2,856 | ​ | $ | 1,570

​

​

12. Capital Stock

Dividends

During the three months ended March 31, 2024, the Board declared and paid cash dividends on the Company’s Series A Preferred Stock and Series B Depositary shares as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Series A Preferred Stock | ​ | Series B Depositary Share | ​ | ​
​ | ​ | Cash Dividend Declared | ​ | Cash Dividend Declared | ​ | ​
Dividend Declaration Date |  | ($ per share) |  | ($ per share) |  | Dividend Payment Date
October 18, 2023 | ​ | $ | 0.53906 | ​ | $ | 0.52344 | ​ | January 15, 2024
February 21, 2024 | ​ | $ | 0.53906 | ​ | $ | 0.52344 | ​ | April 15, 2024

​

BVF Ownership

As of March 31, 2024, BVF owned approximately 31.2% of the Company’s total outstanding shares of common stock, and if all the Series X Convertible Preferred Stock were converted (without taking into account beneficial ownership limitations), BVF would own 51.9% of the Company’s total outstanding shares of common stock. The Company’s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of March 31, 2024, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.

40

Table of Contents

2018 Common Stock ATM Agreement

On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.

​

2021 Series B Preferred Stock ATM Agreement

On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed.

​

Stock Repurchase Program

On January 2, 2024, the Board authorized the Company’s first stock repurchase program, which permits the Company to purchase up to $50.0 million of its common stock through January 2027. Under the program, the Company has discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at the Company’s sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate the Company to acquire any particular amount of its common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. As of March 31, 2024, the Company had purchased a total of 660 shares of its common stock pursuant to the stock repurchase plan for $13,000.

​

13. Income Taxes

No provision was made for federal income taxes, since the Company incurred net operating losses during the three months ended March 31, 2024 and 2023. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets.

The Company had a total of $5.9 million of gross unrecognized tax benefits as of March 31, 2024, none of which would affect the effective tax rate upon realization as it currently has a full valuation allowance against its net deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.

The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through March 31, 2024, the Company had not accrued interest or penalties related to uncertain tax positions.

​

41

Table of Contents

14. Subsequent Events

Kinnate Acquisition

On February 16, 2024, the Company entered into an Agreement and Plan of Merger with Kinnate and XRA, a Delaware corporation and a wholly-owned subsidiary of the Company, pursuant to which the Company acquired Kinnate through a tender offer for (i) $2.5879 in cash per share of Kinnate common stock, plus (ii) one non-transferable contractual contingent value right (“CVR”) per share of Kinnate common stock. The merger closed on April 3, 2024 (the “Merger Closing Date”), and XRA merged with and into Kinnate. Following the merger, Kinnate continued as the surviving corporation in the merger and a wholly owned subsidiary of the Company.

Each Kinnate CVR represents the right to receive potential payments pursuant to the terms and subject to the conditions of the Contingent Value Rights Agreement, dated April 3, 2024 (the “CVR Agreement”), by and among the Company, XRA, a right agent and a representative of the CVR holders. On February 27, 2024, Kinnate sold exarafenib and related IP to Pierre Fabre Medicament, SAS for an upfront cash consideration of $0.5 million and contingent consideration of $30.5 million upon the achievement of certain specified milestones. Kinnate CVR holders will be entitled to 100% of any further net proceeds from this transaction, if any, until the fifth anniversary of the Merger Closing Date, together with 85% of net proceeds, if any, from any license or other disposition of any or all rights to any product, product candidate or research program active at Kinnate as of the closing that occurs within one year of the Merger Closing Date, in each case subject to and in accordance with the terms of the CVR Agreement.

FDA Approval of OJEMDA

On April 23, 2024, Day One announced that the FDA granted approval to Day One’s NDA for OJEMDA (tovorafenib). Pursuant to the Viracta RPA, the Company earned a $9.0 million milestone payment upon FDA approval and is also eligible to receive mid-single-digit royalties on sales of OJEMDA.

Daré Royalty Purchase Agreements

On April 29, 2024, the Company entered into the Daré RPAs. Pursuant to the terms of the Daré RPAs, the Company paid $22.0 million in cash to Daré in consideration for the sale of (a) 100% of all remaining royalties related to XACIATO™ not already subject to the royalty-backed financing agreement Daré entered into in December 2023 and net of payments owed by Daré to upstream licensors, which equates to royalties ranging from low to high single digits, and of all potential commercial milestones related to XACIATO™ that are payable to Daré under that certain Exclusive License Agreement by and between Daré and Organon, dated March 31, 2022, as amended; (b) a 4% synthetic royalty on net sales of OVAPRENE® and a 2% synthetic royalty on net sales of Sildenafil Cream, 3.6%, which will decrease to 2.5% and 1.25%, respectively, upon the Company achieving a pre-specified return threshold; and (c) a portion of Daré’s right to a certain milestone payment that may become payable to Daré under that certain License Agreement between Daré and Bayer HealthCare LLC, dated January 10, 2020. The Daré RPAs also provide for certain milestone payments from the Company to Daré upon achieving a pre-specified return threshold, subject to the terms of the Daré RPAs.

Rezolute Milestone

In April 2024, Rezolute dosed the first patient in its Phase 3 trial of RZ358 and the Company earned a $5.0 million milestone pursuant to our Rezolute License Agreement.

.

​

42

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

This Quarterly Report on From 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on current expectations, estimates and forecasts, as well as our management’s beliefs and assumptions and on information currently available to them, and are subject to risks and uncertainties that are difficult to predict. In some cases you can identify forward-looking statements by words such as “may,” “will,” “should,” “might,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “intend” “goal,” “strategy,” “continue,” “design” and similar words, expressions or the negative of such terms intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: trend analyses and statements regarding future events, future financial performance, anticipated growth, and industry prospects, our future operating expenses, our future losses, the success of our strategy as a royalty aggregator, the assumptions underlying our business model, the extent to which issued and pending patents may protect the products and processes in which we have an ownership or royalty interest and prevent the use of the covered subject matter by third parties, the potential of our existing product candidates to lead to the development of commercial products, our ability to receive potential milestone or royalty payments under license and collaboration agreements and the amount and timing of receipt of those payments, our ability to locate suitable assets to acquire, our ability to complete (on a timely basis or at all) and realize the benefits from acquisitions, uncertainties related to the acquisition of interest in development-stage and clinical-stage product candidates, fluctuations in, our ability to predict our operating results and cash flows, and the sufficiency of our capital resources. Forward-looking statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for our licensees engaged in the development of new products in a regulated market. Among other things: there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s); we may be unable to retain our key employees; litigation, arbitration or other disputes with third parties may have a material adverse effect on us; our product candidates subject to our out-license agreements are still being developed, and our licensees’ may require substantial funds to continue development which may not be available; we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them; products or technologies of other companies may render some or all of our product candidates noncompetitive or obsolete; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market; and we and our licensees are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of our product candidates and could subject us to significant fines and penalties. These and other risks, and uncertainties that may cause our actual results or outcomes to differ materially and adversely from those expressed in our forward-looking statements, including those related to current economic and financial market conditions, are contained principally in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other filings with the SEC.

Forward-looking statements are inherently uncertain and you should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may issue in the future. Except as required by law, we do not undertake any obligation to revise or update publicly any forward-looking statements after completion of the filing of this Quarterly Report on Form 10-Q to reflect later events or circumstances or to reflect the occurrence of unanticipated events, or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review

43

Table of Contents

of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

All references to “portfolio” in this Quarterly Report on Form 10-Q are to milestone and/or royalty rights associated with a basket of product candidates in development.

We use our trademarks, trade names and services marks in this report as well as trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this report appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and trade names.

The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with the audited consolidated financial statements and related notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2023.

Overview

XOMA is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Our portfolio was built through the acquisition of rights to future milestones, royalties and commercial payments, since our royalty aggregator business model was implemented in 2017, combined with out-licensing our proprietary products and platforms from our legacy discovery and development business. Our royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase 1 and 2, with significant commercial sales potential that are licensed to large-cap partners. We also acquire milestone and royalty revenue streams on late-stage clinical assets and commercial assets that are designed to address unmet markets or have a therapeutic advantage, have long duration of market exclusivity, and are expected to deliver a financial return to us in a short timeframe. We expect most of our future revenue to be based on payments we may receive for milestones and royalties associated with these programs.

The generation of future revenues related to licenses, milestone payments, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. We generated a net loss of $8.6 million and net cash used in operating activities was $4.9 million for the three months ended March 31, 2024, and we had an accumulated deficit of $1.2 billion as of March 31, 2024. We generated a net loss of $40.8 million and net cash used in operating activities was $18.2 million for the year ended December 31, 2023.

Recent Business Developments

Kinnate Acquisition

In February 2024, we entered into Agreement and Plan of Merger with Kinnate and XRA pursuant to which we acquired Kinnate through a tender offer for (i) $2.5879 in cash per share of Kinnate common stock plus (ii) one non-transferable contingent value right (“CVR”) per share of Kinnate common stock. The merger closed on April 3, 2024 (the “Merger Closing Date”), and XRA merged with and into Kinnate. Following the merger, Kinnate continued as the surviving corporation in the merger and our wholly owned subsidiary.

Each Kinnate CVR represents the right to receive potential payments pursuant to the terms and subject to the conditions of the Contingent Value Rights Agreement, dated April 3, 2024 (the “CVR Agreement”), by and among the Company, XRA, a right agent and a representative of the CVR holders. In February 2024, Kinnate sold exarafenib and related IP to Pierre Fabre Medicament, SAS for an upfront cash consideration of $0.5 million and contingent consideration of $30.5 million upon the achievement of certain specified milestones. Kinnate CVR holders will be entitled to 100% of any further net proceeds from this transaction, if any, until the fifth anniversary of the Merger Closing Date, together with 85% of net proceeds, if any, from any license or other disposition of any or all rights to any product, product candidate or

44

Table of Contents

research program active at Kinnate as of the closing that occurs within one year of the Merger Closing Date, in each case subject to and in accordance with the terms of the CVR Agreement.

Owen Hughes Appointed as Chief Executive Officer

In January 2024, our Board appointed Owen Hughes as our Chief Executive Officer (Principal Executive Officer) and Jack L. Wyszomierski as Chairman of our Board. Mr. Hughes previously served as our Executive Chairman and Interim Chief Executive Officer beginning on January 1, 2023.

Stock Repurchase Program

On January 2, 2024, our Board authorized our first stock repurchase program, which permits us to purchase up to $50.0 million of our common stock through January 2027. Under the program, we have discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with and Rule 10b5-1 under the Exchange Act, as part of or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at our sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate us to acquire any particular amount of our common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. As of March 31, 2024, we had purchased a total of 660 shares of our common stock pursuant to the stock repurchase program for $13,000.

Portfolio Updates – Royalty and Commercial Payment Purchase Agreements

Daré Royalty Purchase Agreements

On April 29, 2024, we entered into the Daré RPAs, pursuant to which we paid $22.0 million in cash to Daré in consideration for the sale of (a) 100% of all remaining royalties related to XACIATO™ not already subject to the royalty-backed financing agreement Daré entered into in December 2023 and net of payments owed by Daré to upstream licensors, which equates to royalties ranging from low to high single digits, and of all potential commercial milestones related to XACIATO™ that are payable to Daré under that certain Exclusive License Agreement by and between Daré and Organon, dated March 31, 2022, as amended; (b) a 4% synthetic royalty on net sales of OVAPRENE® and a 2% synthetic royalty on net sales of Sildenafil Cream, 3.6%, which will decrease to 2.5% and 1.25%, respectively, upon us achieving a pre-specified return threshold; and (c) a portion of Daré’s right to a certain milestone payment that may become payable to Daré under that certain License Agreement between Daré and Bayer HealthCare LLC, dated January 10, 2020. The Daré RPAs also provide for certain milestone payments from us to Daré upon achieving a pre-specified return threshold, subject to the terms of the Daré RPAs.

Viracta Royalty Purchase Agreement

In April 2024, Day One announced that the FDA granted approval to Day One’s NDA for OJEMDA (tovorafenib). Pursuant to the Viracta RPA, we earned a $9.0 million milestone payment and we are also eligible to receive mid-single-digit royalties on net sales of OJEMDA.

Talphera Commercial Payment Purchase Agreement

In January 2024, we acquired an economic interest in DSUVIA from Talphera for $8.0 million. DSUVIA was approved in 2018 by the FDA for use in adults in certified medically supervised healthcare settings. In April 2023, Talphera divested DSUVIA to Alora for an upfront payment, a 15% royalty on commercial net sales of DSUVIA and up to $116.5 million in sales-based milestone payments under the Talphera APA. In addition, Talphera is entitled to 75% of net sales of DSUVIA to the DoD for its services performed to support sales of DSUVIA to the DoD under the Talphera Marketing Agreement. Under the terms of the agreement, we are entitled to receive (i) 100% of the 15% royalty on commercial net sales and the sales-based milestones related to net sales of DSUVIA, as adjusted, for sales on and after January 1, 2024, and (ii) 100% of Talphera’s future service revenue in the amount of 75% of net sales of DSUVIA to the DoD until we

45

Table of Contents

receive $20.0 million. Thereafter, we will fully retain the 15% royalty on commercial net sales of DSUVIA and will share equally with Talphera the 75% of net sales of DSUVIA to the DoD and the remaining sales-based milestone payments due from Alora.

Affitech Commercial Payment Purchase Agreement

Pursuant to our Affitech CPPA, we are eligible to receive commercial payments under the agreement from Roche consisting of 0.5% of net sales of VABYSMO for a ten-year period following the first commercial sale in each applicable jurisdiction. In 2022, VABYSMO was approved by the FDA and the EMA for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In October 2023, the FDA approved VABYSMO for the treatment of retinal vein occlusion. Payments are due from Roche within 60 days of December 31 and June 30 of each year.

In February 2024, we received $7.4 million representing our commercial payment received from sales of VABYSMO during the last six months of 2023 under the Affitech CPPA. We used these cash receipts to fund contractual interest payments and partially repay the principal balance on our Blue Owl Loan (see Note 8 of the condensed consolidated financial statements).

Based on net sales of VABYSMO in 2023, we paid Affitech sales milestones totaling $6.0 million in March 2024, and we may pay up to an additional $6.0 million in milestones based on the achievement of certain sales thresholds in future periods.

LadRx Agreements

In January 2024, Zevra announced that the FDA accepted its NDA resubmission for arimoclomol and pursuant to the LadRx Agreements, we made a $1.0 million milestone payment to LadRx in January 2024.

Portfolio Updates – License and Collaboration Agreements

Rezolute License Agreement

In April 2024, Rezolute dosed the first patient in its Phase 3 trial of RZ358 and we earned a $5.0 million milestone pursuant to our Rezolute License Agreement.

Critical Accounting Estimates

The preparation of financial statements in accordance with GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We routinely evaluate our estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions and conditions.

Critical accounting estimates are those estimates that involve a significant level of judgment and/or estimation uncertainty and could have or are reasonably likely to have a material impact on our financial condition or results of operations.

There have been no significant changes in our critical accounting estimates during the three months ended March 31, 2024, as compared with those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 8, 2024.

Our significant accounting policies are included in “Note 2 – Basis of Presentation and Significant Accounting Policies” in our condensed consolidated financial statements.

46

Table of Contents

Results of Operations

Revenues

Total revenues for the three months ended March 31, 2024 and 2023, were as follows (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​
​ | ​ | March 31, | ​ | ​
​ | ​ | 2024 |  | 2023 |  | Change
Revenue from contracts with customers | ​ | $ | 1,000 | ​ | $ | — | ​ | $ | 1,000
Revenue recognized under units-of-revenue method | ​ |  | 490 | ​ |  | 437 | ​ | ​ | 53
Total revenues | ​ | $ | 1,490 | ​ | $ | 437 | ​ | $ | 1,053

​

Revenue from Contracts with Customers

Revenue from contracts with customers includes upfront fees, annual license fees and milestone payments related to the out-licensing of our legacy product candidates and technologies. Revenue from contracts with customers for the three months ended March 31, 2024 included milestone payments of $1.0 million pursuant to our license agreement with AVEO. There was no revenue from contracts with customers for the three months ended March 31, 2023.

Revenue Recognized under Units-of-Revenue Method

Revenue recognized under the units-of-revenue method includes the amortization of unearned revenue from the sale of royalty interests to HCRP in 2016. Revenues for the three months ended March 31, 2024 remained consistent with the same period in 2023 due to comparable sales of products underlying the agreements with HCRP.

R&D Expenses

R&D expenses were $33,000 for the three months ended March 31, 2024, compared with $54,000 for the three months ended March 31, 2023. Upon the closing our merger with Kinnate, we assumed operations of Kinnate’s Phase 1 clinical trial of KIN-3248. Few patients remain in the study; however, we expect to incur increased R&D costs during 2024 until the study is completed. We may also incur additional R&D costs related to stability studies and storage of the remaining programs transferred through our Kinnate acquisition.

G&A Expenses

G&A expenses include salaries and related personnel costs, professional fees, and facilities costs. For the three months ended March 31, 2024, G&A expenses were $8.5 million compared with $6.2 million for the three months ended March 31, 2023. The increase of $2.3 million was primarily due to a $1.3 million increase in stock-based compensation and a $0.7 million increase in consulting and legal expenses. The increase in stock-based compensation expenses was largely due to the PSU grant associated with the appointment of Mr. Hughes as our full-time Chief Executive Officer in January 2024 combined with PSUs granted in May 2023. We expect G&A expenses to further increase in 2024 due to an anticipated increase in activity related to our evaluation of potential royalty acquisitions and anticipated costs associated with our Kinnate acquisition.

Arbitration Settlement Costs

Arbitration settlement costs of $4.1 million for the three months ended March 31, 2023 consisted of the costs incurred related to the settlement of an arbitration proceeding with one of our licensees in the first quarter of 2023. There were no arbitration settlement costs for the three months ended March 31, 2024.

47

Table of Contents

Other Income (Expense)

Interest Expense

The accretion of debt discount and debt issuance costs is included in interest expense. Interest expense is shown below for the three months ended March 31, 2024 and 2023 (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​
​ | ​ | March 31, | ​ | ​
​ |  | 2024 |  | 2023 |  | Change
Accrued interest expense | ​ | $ | 3,245 | ​ | $ | — | ​ | $ | 3,245
Accretion of debt discount and debt issuance costs | ​ |  | 306 | ​ |  | — |  | ​ | 306
Total interest expense | ​ | $ | 3,551 | ​ | $ | — | ​ | $ | 3,551

​

We had no debt outstanding or interest expense incurred until we executed the Blue Owl Loan Agreement on December 15, 2023. The $3.6 million interest expense for the three months ended March 31, 2024 represents interest incurred on the Blue Owl Loan since December 31, 2023. Interest expense is expected to continue in future quarters so long as the Blue Owl Loan remains outstanding.

Other Income (Expense), Net

The following table shows our activity in other income (expense), net for the three months ended March 31, 2024 and 2023 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended |  | ​
​ | ​ | March 31, | ​ | ​
​ | ​ | 2024 |  | 2023 | ​ | Change
Other income (expense), net |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Investment income | ​ | $ | 1,708 | ​ | $ | 381 | ​ | $ | 1,327
Change in fair value of equity securities | ​ | ​ | 252 | ​ | ​ | (24) | ​ | ​ | 276
Total other income (expense), net | ​ | $ | 1,960 | ​ | $ | 357 | ​ | $ | 1,603

​

Investment income increased by $1.3 million for the three months ended March 31, 2024 compared with the three months ended March 31, 2023 due to higher balances and higher market interest rates on our investments. For the three months ended March 31, 2024 and 2023, the change in fair value of equity securities was due to the change in market price of shares of Rezolute’s common stock.

Provision for Income Taxes

We recorded no provision for federal income tax, since we incurred net operating losses during the three months ended March 31, 2024 and 2023. We continue to maintain a full valuation allowance against our remaining net deferred tax assets. We had a total of $5.9 million of gross unrecognized tax benefits, none of which would impact our effective tax rate to the extent that we continue to maintain a full valuation allowance against our deferred tax assets. We do not expect our unrecognized tax benefits to change significantly over the next twelve months.

48

Table of Contents

Liquidity and Capital Resources

The following table summarizes our cash and cash equivalents, our working capital and our cash flow activities as of and for each of the periods presented (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | December 31, | ​ | ​ | ​
​ |  | 2024 |  | 2023 |  | Change
Cash and cash equivalents(1) | ​ | $ | 136,225 | ​ | $ | 153,290 | ​ | $ | (17,065)
Working capital | ​ | $ | 131,350 | ​ | $ | 149,814 | ​ | $ | (18,464)

​

| (1) | Unrestricted.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​
​ | ​ | March 31, | ​ | ​ | ​
​ |  | 2024 |  | 2023 |  | Change
Net cash used in operating activities | ​ | $ | (4,947) | ​ | $ | (4,924) | ​ | $ | (23)
Net cash used in investing activities | ​ |  | (7,246) | ​ | ​ | (7,234) | ​ |  | (12)
Net cash used in financing activities | ​ |  | (4,956) | ​ |  | (1,368) | ​ |  | (3,588)
Net decrease in cash, cash equivalents and restricted cash | ​ | $ | (17,149) | ​ | $ | (13,526) | ​ | $ | (3,623)

​

​

Net cash used in operating activities for the three months ended March 31, 2024 was $4.9 million and primarily consisted of our operating expenses of $8.5 million partially offset by non-cash expenses of $3.0 million, which primarily consisted of stock-based compensation expense of $2.9 million, and a $1.0 million milestone payment received pursuant to our license agreement with AVEO. Net cash used in operating activities for the three months ended March 31, 2023 was $4.9 million and primarily consisted of our operating expenses of $10.6 million, partially offset by non-cash expenses of $2.0 million, which primarily consisted of stock-based compensation expense of $1.6 million, offset by a $2.9 million change in assets and liabilities.

Net cash used in investing activities for the three months ended March 31, 2024 was $7.2 million, and primarily consisted of a $8.0 million payment to Talphera for the acquisition of payment rights pursuant to the Talphera CPPA in January 2024, a $6.0 million payment to Affitech for sales milestones pursuant to the Affitech CPPA in January 2024 and a $1.0 million payment to LadRx for the achievement of a regulatory milestone pursuant to the LadRx Agreements in January 2024, partially offset by a $7.4 million commercial payment received from Roche pursuant to the Affitech CPPA and a $0.4 million commercial payment received pursuant to the Aptevo CPPA. Net cash used in investing activities for the three months ended March 31, 2023 was $7.2 million, and primarily consisted of $9.6 million for the acquisition of payment rights pursuant to the Aptevo CPPA in March 2023, partially offset by a $2.4 million commercial payment received from Roche pursuant to the Affitech CPPA.

Net cash used in financing activities for the three months ended March 31, 2024 was $5.0 million and primarily consisted of principal payments of $3.6 million on the Blue Owl Loan, dividends of $1.4 million on our Series A and Series B Preferred Stock, and $0.6 million in debt issuance costs and loan fees paid in connection with long-term debt partially offset by $0.6 million in proceeds from the exercise of options, net of taxes paid. Net cash used in financing activities for the three months ended March 31, 2023 was $1.4 million, and consisted of dividends on our Series A and Series B Preferred Stock.

​

Capital Resources

We have incurred significant operating losses since our inception and as of March 31, 2024, we had an accumulated deficit of $1.2 billion. As of March 31, 2024, we had $136.2 million in cash and cash equivalents and $6.2 million in restricted cash. Based on our current cash balance and our planned discretionary spending, such as royalty acquisitions, we believe that our current financial resources are sufficient to fund our planned operations, commitments, and contractual obligations for a period of at least one year following the filing date of this report.

​

49

Table of Contents

We have primarily financed our operations and acquisitions through debt facilities, the issuance of our common stock, Series A and Series B Preferred Stock, and amounts received as milestone payments under our license agreements. In December 2023, XRL entered into the Blue Owl Loan Agreement (see Note 8 to the condensed consolidated financial statements and further details below in “Long-Term Debt”). We intend to use the net cash received from the Blue Owl Loan, together with our existing capital resources, to fund our ongoing operations, to repurchase common stock and for working capital and other general corporate purposes.

​

The generation of future revenues related to licenses, milestone payments, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Milestone payments earned in prior periods are not indicative of anticipated milestone payments in future periods. We may seek additional capital through our 2018 Common Stock ATM Agreement or our 2021 Series B Preferred Stock ATM Agreement (see Note 12 to the condensed consolidated financial statements), or through other public or private debt or equity transactions. Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common and preferred stock, which are subject to a number of development and business risks and uncertainties, our creditworthiness and whether were are able to raise such additional capital at a price or on terms that are favorable to us, if at all. If we are unable to raise additional funds when we need them, our business and operations may be adversely affected.

Material Cash Requirements

Our material cash requirements in the short and long term consist of the following:

​

Operating expenditures: Our primary uses of cash and our operating expenses include employee and related costs, consultant fees to support our administrative and business development efforts, legal and accounting fees, insurance costs and costs associated with our investor relations and IT services. Our planned spending includes increased personnel-related costs associated with the appointment of Mr. Hughes to Chief Executive Officer in a full-time capacity.

​

To support our royalty aggregator business model, we engage third parties to assist in the evaluation of potential acquisitions of milestone payments and royalty streams. Additional operating expenses, including consulting and legal costs, may increase in 2024 in response to an anticipated increase in the volume of acquisition targets evaluated or completed.

​

In June 2023 we entered into a lease for our headquarters in Emeryville, California. The lease commenced in November 2023 and has a term of 65 months. As of March 31, 2024, we expect to incur incremental undiscounted costs of $0.5 million associated with our building lease.

​

We will be required to make future R&D and G&A expenditures related to the obligations and liabilities we assumed in the Kinnate acquisition. We expect these costs to be funded in full by the cash we received upon close of the merger.

​

Share Repurchase Program: On January 2, 2024, our Board authorized our first stock repurchase program, which permits us to purchase up to $50.0 million of our common stock through January 2027. As of March 31, 2024, we had purchased a total of 660 shares of common stock pursuant to the stock repurchase program for $13,000.

​

Long-Term Debt: Under the Blue Owl Loan Agreement, the outstanding principal balance will bear interest at an annual rate of 9.875%. XRL began making payments of interest under the Blue Owl Loan Agreement semi-annually, in March 2024 using the royalties received on worldwide net sales of VABYSMO, pursuant to the Affitech CPPA. On each interest payment date, any shortfall in interest payment will be paid from the interest reserve, any uncured shortfall in interest payment that exceeds the interest reserve will increase the outstanding principal amount of the loan, and any royalty payments in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. As of March 31, 2024, XRL held restricted cash of $6.2 million in reserve accounts that may only be used to pay interest and administrative fees and XRL’s operating expenses pursuant to the Blue Owl Loan Agreement. As of March 31, 2024, the current and non-current portion of the initial term loan was $6.1 million and $114.5 million, respectively, and $0.2 million and $6.0 million of the restricted cash is classified as current and non-current, respectively.

50

Table of Contents

​

RPAs, AAAs and CPPAs: A significant component of our business model is to acquire rights to potential future milestone payments and royalty payment streams. We expect to continue deploying capital toward these acquisitions in the near and long term.

​

We have paid $1.0 million for a milestone payment due under our agreement with LadRx in January 2024 and $6.0 million for sales milestones due under our agreement with Affitech in March 2024. We have up to an additional $3.0 million and $5.0 million in milestone payments that may become due under the Affitech CPPA and LadRx Agreement, respectively. We currently have $3.0 million of contingent consideration recorded on our condensed consolidated balance sheets as of March 31, 2024.

​

In addition, we have potential sales-based milestone payments that may become due under our agreements with Aronora and Kuros. All of these milestones and royalty payments represent a portion of the funds we may receive in the future pursuant to these agreements, and therefore we expect these payments to be fully funded by the related royalty or commercial payment receipts.

Collaborative Agreements, Royalties and Milestone Payments: We may need to make potential future milestone payments and pay legal fees to third parties as part of our licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by our licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on our condensed consolidated balance sheet as of March 31, 2024. We are unable to determine precisely when and if our payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. We expect all payments due to be funded by a portion of the related milestone or royalty revenue we receive or we expect these payments to be reimbursed by our licensees.

Dividends: Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per share of Series A Preferred Stock per year). Holders of Series B Depositary Shares are entitled to receive, when and as declared by our Board, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year, which is equivalent to $2,093.75 per year per share of Series B Preferred Stock ($2.09375 per year per depositary share). Dividends on the Series A and Series B Preferred Stock are payable in arrears on or about the 15th day of January, April, July and October of each year. Since original issuance, all dividends have been paid as scheduled. We expect to continue making these dividend payments as scheduled using our existing capital resources.

Changes in Commitments and Contingencies

Our commitments and contingencies were reported in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC and there have been no material changes during the three months ended March 31, 2024 from the commitment and contingencies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

​

51

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer (our Principal Executive Officer) and our Senior Vice President, Finance and Chief Financial Officer (our Principal Financial and Accounting Officer), we conducted an evaluation of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this report. Our disclosure controls and procedures are intended to help ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Senior Vice President, Finance and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures. Based on this evaluation, our Chief Executive Officer and our Senior Vice President, Finance and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

PART II – OTHER INFORMATION

​

ITEM 1. LEGAL PROCEEDINGS

We are not currently engaged in any legal proceedings that, in the opinion of our management, if determined adversely to us, would individually or taken together, have a material adverse effect on our business, results of operations, financial position or cash flows. However, from time to time, we may become involved in litigation, arbitration or other proceedings relating to claims arising from the ordinary course of business.

We may become involved in material legal proceedings in the future, and the potential impact on us of any on-going proceeding which we do not currently believe to be material could become material. Such matters are subject to significant uncertainties, and there can be no assurance that any legal proceedings in which we are or may become involved will not have a material adverse effect on our business, results of operations, financial position or cash flows.

​

ITEM 1A. RISK FACTORS

Except as discussed below, there have been no material changes in our risk factors as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. For a detailed description of our risk factors, refer to Part I, Item IA, “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Our potential milestone and royalty providers may rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could affect our potential milestone and royalty providers’ product candidate development.

Third parties provide services in connection with preclinical and clinical development programs, including in vitro and in vivo studies, assay and reagent development, immunohistochemistry, toxicology, pharmacokinetics, clinical trial support, manufacturing and other outsourced activities. If these service providers do not adequately perform the services for which our potential milestone and royalty providers have contracted, or cease to continue operations, and our potential milestone and royalty partners are not able to find a replacement provider quickly or lose information or items associated with their product candidates, our potential milestone and royalty providers’ development programs and receipt of any potential resulting income may be delayed.

52

Table of Contents

In addition, our potential milestone or royalty providers may currently or in the future rely on foreign contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”). Such foreign CROs or CMOs may be subject to U.S. legislation, including the proposed BIOSECURE Bill, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to our potential milestone or royalty providers, delay the procurement or supply of such material, have an adverse effect on their ability to secure significant commitments from governments to purchase potential products or disrupt the supply chain. If our potential milestone or royalty providers are not able to secure supply of their products or product candidates as a result of the BIOSECURE Bill or other applicable legislation and fail to maintain timely progress on their clinical development programs, regulatory submissions or commercialization activities, they may be unable to deliver milestone or royalty payments to us in a timely manner or at all, and this could adversely affect our business, financial condition, results of operations and cash flows.

For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on the collaborators of our potential milestone or royalty providers that operate in China, which, in turn, could have an adverse effect on such milestone or royalty providers and, in turn, our business, financial condition, results of operations and prospects. Evolving changes in China’s public health, economic, political, and social conditions and the uncertainty around China’s relationship with other governments, such as the United States and the U.K., could also negatively impact our potential milestone or royalty providers, including impacting their ability to manufacture products or product candidates, their ability to secure government funding or their ability to maintain timely progress on their clinical development programs, regulatory submissions or commercialization activities.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

None.

Issuer Purchases of Equity Securities

On January 2, 2024, the Board authorized our first stock repurchase program, which permits us to purchase up to $50.0 million of our common stock through January 2027. Under the program, we have discretion in determining the conditions under which shares may be purchased from time to time, including through transactions in the open market, in privately negotiated transactions, under plans compliant with Rule 10b5-1 under the Exchange Act, or by other means in accordance with applicable laws. The manner, number, price, structure, and timing of the repurchases, if any, will be determined at our sole discretion and repurchases, if any, depend on a variety of factors, including legal requirements, price and economic and market conditions, royalty and milestone acquisition opportunities, and other factors. The repurchase authorization does not obligate us to acquire any particular amount of our common stock. The Board may suspend, modify, or terminate the stock repurchase program at any time without prior notice. All common stock repurchased by us during the three months ended March 31, 2024 was subsequently retired. Our repurchases of our common stock during the three months ended March 31, 2024 was as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Period | ​ | Total Number of Shares Purchased (1) | ​ | Average Price Paid per Share (2) | ​ | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | ​ | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
January 2 – January 31, 2024 |  | ​ | — |  | $ | — | ​ | ​ | — | ​ | $ | 50,000,000
February 1 – February 29, 2024 |  | ​ | 660 |  | $ | 19.88 | ​ | ​ | 660 | ​ | $ | 49,986,899
March 1 – March 31, 2024 | ​ | ​ | — | ​ | $ | — | ​ | ​ | — | ​ | $ | 49,986,899
Total |  | ​ | 660 |  | $ | 19.88 | ​ | ​ | 660 | ​ | $ | 49,986,899

​

| (1) | The number of shares purchased is based on the settlement date.

| (2) | Average price per share includes commissions.

​

53

Table of Contents

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

​

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

​

ITEM 5. OTHER INFORMATION

c) Trading Plans

During the fiscal quarter ended March 31, 2024, no director or Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K).

​

54

Table of Contents

ITEM 6. EXHIBITS

​ | ​ | ​ | ​ | Incorporation By Reference
--- | --- | --- | --- | ---
Exhibit Number |  | Exhibit Description |  | Form |  | SEC File No. |  | Exhibit |  | Filing Date
2.1 | ​ | Agreement and Plan of Merger between the Company, Kinnate and Merger Sub, dated February 16, 2024 | ​ | 8-K | ​ | 001-39801 | ​ | 2.1 | ​ | 2/16/2024
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2.2 | ​ | Contingent Value Rights Agreement, dated April 3, 2024, by and between XOMA Corporation, XRA 1 Corp., Broadridge Corporate Issuer Solutions, LLC and Fortis Advisors LLC. | ​ | 8-K | ​ | 001-39801 | ​ | 2.2 | ​ | 4/3/2024
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
3.1 |  | Certificate of Incorporation of XOMA Corporation |  | 8-K12G3 |  | 000-14710 |  | 3.1 |  | 01/03/2012
3.2 |  | Certificate of Amendment of Certificate of Incorporation of XOMA Corporation |  | 8-K |  | 000-14710 |  | 3.1 |  | 05/31/2012
3.3 | ​ | Certificate of Amendment of Amended Certificate of Incorporation of XOMA Corporation | ​ | 8-K | ​ | 000-14710 | ​ | 3.1 | ​ | 05/28/2014
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
3.4 | ​ | Certificate of Amendment to the Amended Certificate of Incorporation of XOMA Corporation | ​ | 8-K | ​ | 000-14710 | ​ | 3.1 | ​ | 10/18/2016
3.5 | ​ | Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock | ​ | 8-K | ​ | 000-14710 | ​ | 3.1 | ​ | 02/16/2017
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
3.6 | ​ | Certificate of Designation of 8.625% Series A Cumulative Perpetual Preferred Stock | ​ | 8-K | ​ | 000-14710 | ​ | 3.1 | ​ | 12/11/2020
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
3.7 | ​ | Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock | ​ | 8-K | ​ | 001-39801 | ​ | 3.1 | ​ | 04/08/2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
3.8 | ​ | Certificate of Correction of the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock | ​ | 10-Q | ​ | 001-39801 | ​ | 3.8 | ​ | 08/05/2021
3.9 | ​ | Certificate of Amendment to the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock of XOMA Corporation. | ​ | 8-K | ​ | 001-39801 | ​ | 3.1 | ​ | 08/05/2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
3.10 | ​ | By-laws of XOMA Corporation | ​ | 8-K12G3 | ​ | 000-14710 | ​ | 3.2 | ​ | 01/03/2012
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.1 |  | Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9 and 3.10 |  | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.2 | ​ | Specimen of Common Stock Certificate | ​ | 8-K | ​ | 000-14710 | ​ | 4.1 | ​ | 01/03/2012
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.3 | ​ | Deposit Agreement, dated effective April 9, 2021, by and among XOMA Corporation, American Stock Transfer & Trust Company, LLC, as depositary, and the holders of the depositary receipts issued thereunder | ​ | 8-K | ​ | 001-39801 | ​ | 4.1 | ​ | 04/08/2021
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.4 | ​ | Form of Warrants (May 2018 Warrants) | ​ | 10-Q | ​ | 000-14710 | ​ | 4.6 | ​ | 08/07/2018
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.5 | ​ | Form of Warrants (March 2019 Warrants) | ​ | 10-Q | ​ | 000-14710 | ​ | 4.7 | ​ | 05/06/2019
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.6 | ​ | Form of Warrant (December 2023) ($35.00 Exercise Price) | ​ | 8-K | ​ | 001-39801 | ​ | 4.1 | ​ | 12/19/2023
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

55

Table of Contents

​ | ​ | ​ | ​ | Incorporation By Reference
--- | --- | --- | --- | ---
Exhibit Number |  | Exhibit Description |  | Form |  | SEC File No. |  | Exhibit |  | Filing Date
4.7 | ​ | Form of Warrant (December 2023) ($42.50 Exercise Price) | ​ | 8-K | ​ | 001-39801 | ​ | 4.2 | ​ | 12/19/2023
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.8 | ​ | Form of Warrant (December 2023) ($50.00 Exercise Price) | ​ | 8-K | ​ | 001-39801 | ​ | 4.3 | ​ | 12/19/2023
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
4.9 | ​ | Form of Indenture | ​ | S-3 | ​ | 333-277794 | ​ | 4.6 | ​ | 3/8/2024
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
10.1 | ​ | Amended and Restated Officer Employment Agreement, dated January 8, 2024, between XOMA Corporation and Owen Hughes | ​ | 10-K | ​ | 001-39801 | ​ | 10.16 | ​ | 3/8/2024
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
10.2#+ | ​ | Payment Interest Purchase Agreement by and between Talphera, Inc. and XOMA (US) LLC dated as of January 12, 2024 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
10.3#+ | ​ | Amendment No. 1 to Royalty Purchase Agreement entered into as of March 4, 2024 by and between Viracta Therapeutics, Inc (“Seller”) and XOMA (US) LLC (“Purchaser”) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
31.1+ | ​ | Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
31.2+ |  | Certification of Chief Financial Officer, as required by Rule 13a 14(a) or Rule 15d 14(a) of the Securities Exchange Act of 1934 |  |  |  |  |  |  |  |
32.1+(1) |  | Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. §1350 |  |  |  |  |  |  |  |
101.INS+ | ​ | Inline XBRL Instance Document | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
101.SCH+ |  | Inline XBRL Schema Document |  |  |  |  |  |  |  |
101.CAL+ |  | Inline XBRL Calculation Linkbase Document |  |  |  |  |  |  |  |
101.DEF+ |  | Inline XBRL Definition Linkbase Document |  |  |  |  |  |  |  |
101.LAB+ |  | Inline XBRL Labels Linkbase Document |  |  |  |  |  |  |  |
101.PRE+ |  | Inline XBRL Presentation Linkbase Document |  |  |  |  |  |  |  |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
104 | ​ | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​

+ | Filed herewith.

# Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential.

(1) | Furnished herewith. These certifications are not deemed filed with the SEC and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Form 10-Q), irrespective of any general incorporation language contained in such filing.

​

56

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| XOMA Corporation
Date: May 9, 2024 | By: | /s/ OWEN HUGHES
|  | Chief Executive Officer (Principal Executive Officer)
​ | ​ | ​
Date: May 9, 2024 | By: | /s/ THOMAS BURNS
|  | Thomas Burns Senior Vice President, Finance and Chief Financial Officer (Principal Financial and Principal Accounting Officer)

​

​

​

​

57